

CURRICULUM VITAE

Name Andrew (Andy) Roger Willan

Address Child Health Evaluative Sciences, SickKids Research Institute
555 University Avenue, Toronto ON M5G 1X8 Canada

Telephone +1.416.813.2166

Fax +1.416.813.5979

E-mail andy@andywillan.com

Website www.andywillan.com

Education

PhD in Biostatistics from the Department of Epidemiology and Biostatistics at the University of Western Ontario, London ON, 1979.

MSc in Statistics from Queen's University, Kingston ON, 1976.

BEd in Mathematics and Physical Education from Queen's University, Kingston ON, 1972.

BA in Economics and Mathematics from York University, Toronto ON, 1970.

Present Position as of July 2002

Senior Scientist, Child Health Evaluative Sciences, SickKids Research Institute,
Toronto
Professor, Dalla Lana School of Public Health, University of Toronto
Professor Emeritus, Clinic Epidemiology and Biostatistics, McMaster University

Awards

Co-author on a paper receiving the International Society for Pharmaco-economics and Outcomes Research Award for Methodology Excellence, awarded May 2003.

Co-author on a paper receiving the International Society for Pharmaco-economics and Outcomes Research Award for Methodology Excellence, awarded May 2002.

First author on a paper receiving the International Society for Pharmaco-economics and Outcomes Research Award for Methodology Excellence, awarded May 2000.

Co-author on a paper receiving the Best Paper Award from the Society for Medical Decision Making, 1995.

NHRDP Graduate Fellowship, 1977-1980.

Experience

September 1993 to June 2002 - Professor, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton ON

September 1990 to June 1993 - Associate Professor, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton ON

January 1989 to May 1990 - Head, Division of Clinical Trials and Epidemiology, Sunnybrook Health Science Centre, Toronto ON

March 1989 to October 1991 - Associate Professor, Department of Preventive Medicine and Biostatistics, University of Toronto, Toronto ON

September 1987 to February 1989 - Associate Professor, Department of Population Medicine, University of Guelph, Guelph ON

April 1985 to August 1987 - Head of Biometry with the Clinical Trials Group, National Cancer Institute of Canada, Queen's University, Kingston ON.

September 1981 to August 1987 - Assistant Professor, Department of Community Health and Epidemiology, Queen's University, Kingston ON.

October 1980 to March 1985 - Biostatistician with the Clinical Trials Group, National Cancer Institute of Canada, Queen's University, Kingston ON

December 1979 to September 1980 - Biostatistician with the Division of Epidemiology at the Cancer Control Agency of British Columbia, Vancouver BC

January 1980 to September 1980 - Assistant Professor, Department of Mathematics, University of British Columbia, Vancouver BC

September 1976 to November 1979 - Statistical consultant for numerous research projects, covering the fields of Pharmacology, Epidemiology, Physiology, Dentistry and Occupational Therapy, University of Western Ontario, London ON

September 1974 to April 1976 - Instructor of Mathematics at Queen's University, Kingston ON

January 1974 to June 1974 - Teacher of Mathematics at Palmers College, Grays, Essex, England

September 1970 to June 1971 - Teacher of Mathematics at Glendale Secondary School, Hamilton ON

Journal Articles

(**PA**—Principal Author; **CPA**—Co-principal Author; **SRA**—Senior Responsible Author; **C**—Coauthor) (Research trainees underlined)

1. **Willan A**, Watts D. Meaningful multicollinearity measures. *Technometrics* 1978;**20**:407-412. **PA**
2. Posthuma B, **Willan A**. Academic performance and job satisfaction. *Can J Occup Ther* 1981; **48**:83-86. **CPA**
3. **Willan A**. Relative efficiency in survival analysis. *J Chron Dis* 1983; **36**:183-192. **PA**
4. Fried P, Watkinson B, **Willan A**. Marijuana use during pregnancy and decreased length of gestation. *Amer J Obstet Gynaecol* 1984; **150**:23-27. **C**
5. Stewart T, Shelley W, **Willan A**, Hollingshead A. An evaluation of the role of tumour specific antigens in lung cancer. *Annual Clinical Conference on Cancer* 1984; **28**:351-374. **C**
6. Pater J, **Willan A**. Clinical trials as diagnostic tests. *Control Clin Trials* 1984; **5**:107-113. **CPA**
7. Pater J, **Willan A**. Methodologic issues in trials of antiemetics. *J Clin Oncol* 1984; **2**:484-487. **CPA**
8. **Willan A**, Pater J. Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. *J Chron Dis* 1985; **38**:603-608. **PA**
9. Rhedda A, McCans J, **Willan A**, Ford P. A double-blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. *J Rheumatol* 1985; **12**:724-727. **C**

10. Feld R, Louie TJ, Mandell L, Bow EJ, Robson HG, Chow A, Belch A, Miedzinski L, Rachlis A, Pater J, Willan AR. A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. *Arch Int Med* 1985; **145**:1083-1088. **C**
11. Anderson J, **Willan A**, Gancher W. The negative binomial model and the denominator problem in rural family practice. *Fam Pract* 1986; **3**:174-183. **CPA**
12. Osoba D, Erlichman C, **Willan A**, Levitt M, Pater J. Superiority of methylprednisolone sodium succinate over conventional dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. *Clin Invest Med* 1986; **9**:225-231. **CPA**
13. Evans W, Feld R, Murray N, Pater J, Shelley W, **Willan A**, Osoba D, Levitt M, Coy P, Hodson I, Payne D, MacDonald A. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. *Semin Oncol* 1986; **13**(Suppl 3):10-16. **C**
14. Pater J, Eisenhauer E, Shelley W, **Willan A**. Testing hypotheses in clinical trials: The National Cancer Institute of Canada Clinical Trials Group Experience. *Cancer Treat Rep* 1986; **70**:1133-1135. **CPA**
15. **Willan A**, Pater J. Carryover and the two-period crossover clinical trial. *Biometrics* 1986; **42**:593-599. **PA**
16. **Willan A**, Pater J. Using baseline measurements in the two period crossover clinical trial. *Control Clin Trials* 1986; **7**:282-289. **PA**
17. Pater J, Carmichael J, Krepart G, Fraser R, Roy M, Levitt M, Brown L, Wilson K, Shelley W, **Willan A**. Second-line chemotherapy of stage III-IV ovarian carcinoma: A randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. *Cancer Treat Rep* 1987; **71**:277-281. **C**
18. Shelley W, Carmichael J, Brown L, Fraser R, Kirk M, Krepart G, Levitt M, Roy M, **Willan A**, Wilson K. Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. *Gynaecol Oncol* 1987; **29**:208-221. **C**
19. Carmichael J, Shelley W, Brown L, Fraser R, Kirk M, Krepart G, Levitt M, Roy M, **Willan A**, Wilson K. A predictive index of cure versus no cure in advanced ovarian carcinoma patients--replacement of second-look laparotomy as a diagnostic test. *Gynaecol Oncol* 1987; **27**:269-278. **C**
20. Evans W, Feld F, Murray N, **Willan A**, Coy P, Osoba D, Sheppard F, Clark D, Levitt M, MacDonald A, Wilson K, Shelley W, Pater J. A Canadian multicentre randomized trial comparing standard and alternating administration of two non-cross resistant

- chemotherapy combinations in patients with extensive small cell lung cancer. *Ann Intern Med* 1987; **107**:451-458. **C**
21. Wilson K, Shelley W, Belch A, Brandes L, Bergsagel D, Klimo P, White D, **Willan A**. Weekly cyclophosphamide and alternate day prednisone: An effective secondary therapy in multiple myeloma. *Cancer Treat Rep* 1987; **71**:981-982. **C**
 22. Burnett R, **Willan A**. Linear rank tests for randomized block designs. *Communications in Statistics A* 1988; **17**:2455-2470. **CPA**
 23. **Willan A**. Using the maximum test statistic in the two period crossover clinical trial. *Biometrics* 1988; **44**:211-218. **PA**
 24. **Willan A**, MacKenzie T. The severity of illness and laboratory testing. *Can J Public Health* 1988; **79**:435-439. **PA**
 25. Cuess A, **Willan A**, Canny C, Gomolin J, Harvey P, Gonder J, Britton W, Howcroft M, Leonard B, Chew E, Mandelcorn M, Martin J, Chisholm L, Moffat K, Desroches G, Siebert L, Schwartz C, Boucher C, Dumas J, Labelle P, Kozousek V, Grant G, Schindler R, Marcil G, Shea M, Williams J. Argon (green) versus krypton (red) laser photocoagulation of subretinal neovascularization. *Retinal Dis* 1988; **2**:19-25. **CPA**
 26. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, **Willan A**. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. *Br J Cancer* 1988; **57**:94-99. **C**
 27. Burns B, Comrie W, **Willan A**, McCaughey E. Observer variation in the pathological diagnosis of malignant lymphoma in Canada. *Cancer* 1988; **62**:314-318. **C**
 28. Anderson J, **Willan A**. Estimating the size of family practice population: Quadratic odds estimation. *Med Care* 1988; **26**:1228-1233. **CPA**
 29. Rapp E, Pater J, **Willan A**, Cormier Y, Murray N, Evans W, Hodson I, Clark D, Feld R, Arnold A, Ayoub J, Wilson K, Latreille J, Wierzbicki R, Hill D. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicentre randomized trial. *J Clin Oncol* 1988; **6**:633-641. **C**
 30. Osoba D, Erlichman C, **Willan A**, Brigden M, Geggie P, Pater J, Rusthoven J, Wilson K. Failure of methylprednisolone acetate to prolong the anti-nauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy. *Clin Invest Med* 1988; **11**:377-379. **C**
 31. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y, **Willan A**. Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy, melphalan and intraperitoneal chronic phosphate. *J Clin Oncol* 1988; **6**:1254-1263. **C**

32. Ryan C, Wherrett B, **Willan A**. Home Nebulizers in Childhood Asthma: Parents Perceptions and Practices. *Clin Pediatr (Phila)* 1988; **27**:420-424. **C**
33. Whiting T, Viel L, McDonell W, **Willan A**, Tesarowski D. Repeatability of the partial expired flow-volume loop in horses with exercise induced pulmonary haemorrhage. *Am J Vet Res* 1988 (accepted for publication). **C**
34. Waltner-Toews D, **Willan A**. Seasonal variation of transmission risk of Lyme disease and human babesiosis. *Am J Epidemiol* 1988; **128**:1383-1384. **C**
35. Cruess A, Williams J, **Willan A**. Argon green and krypton red laser treatment of diabetic macular edema. *Can J Ophthal* 1988; **23**:262-266. **CPA**
36. Lissemore K, Leslie K, McBride K, Burton J, **Willan A**, Bateman K. Observations on intramammary infection and somatic cell counts in cows treated with recombinant bovine somatotropin. *Can J Vet Res* 1990; **55**:196-198. **C**
37. Holberg D, Palmer N, Vanpelt D, **Willan A**. A comparison of manual and power-assisted thoracolumbar disc fenestration in dogs. *Vet Surg* 1990; **19**:323-327. **C**
38. MacKenzie T, **Willan A**, Cox M, Green A. Indirect costs of teaching in Canadian hospitals. *Can Med Assoc J* 1991; **144**:149-152. **CPA**
39. Warr D, **Willan A**, Fine S, Wilson K, Davis A, Erlichman C, Rusthoven J, Osoba D, Laberge F, Latrielle J, Pater J. Granisetron is superior to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. *J Natl Cancer Inst* 1991; **83**:1169-1173. **CPA**
40. **Willan A**, Ross W, MacKenzie T. A comparison of in-patient classification systems: A problem on non-nested regressions. *Stat Med* 1992; **11**:1321-1331. **PA**
41. Guyatt G, Oxman A, Ali M, **Willan A**, McIlroy W, Patterson C. Laboratory diagnosis of iron deficiency anaemia-An overview. *J Gen Intern Med* 1992; **7**:145-153. **C**
42. Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, Mcculloch PB, Mcpherson TA, Paterson AHG, Prentice R, Silver HKB, **Willan AR**, Wilson K, Zee. Improved survival in patients with poor-prognosis malignant-melanoma treated with adjuvant levamisole - a phase-iii study by the national-cancer-institute-of-canada clinical-trials group. *J Clin Oncol* 1991; **9**:729-735. **C**
43. Yelle L, Bergsagel D, Basco V, Brown T, Bush R, Gillies J, Israels L, Miller A, Rideout D, Whitelaw D, **Willan AR**, Pater J. Combined modality therapy of hodgkins-disease - 10-year results of national-cancer-institute-of-canada clinical-trials group multicenter clinical-trial. *J Clin Oncol* 1991; **9**:1983-1993. **C**

44. Molloy W, Guyatt G, Alemayehu E, McIlroy W, **Willan A**, Eisemann M, Gergrehiwot A, Basile J, Penington G, McMurdo M, Finucane P, Zelmanowicz A, Hyland M. Factors affecting Physicians' decisions on caring for a incompetent elderly patient: An international study. *Can Med Assoc J* 1991; **145**:947-952. **C**
45. Hannah M, Hannah W, Hellman J, Hewson S, Milner R, **Willan A**. Induction of labour vs serial antenatal monitoring in postterm pregnancy: A randomized controlled trial. *N Engl J Med* 1992; **326**:1587-1592. **C**
46. Cook DJ, Ali MAM, Allen C, Baxter F, Bradley C, Davis C, Egier B, Gibson J, Guyatt G, Hamielec C, Hewson J, Jaeschke R, Killian K, Lindblad T, Mcilroy W, McLellan A, Morse J, Panju A, Powles P, Puksa S, Ryley A, Stallwood G, Stubbing D, **Willan AR**. Physicians' perception of laboratory costs in the intensive care unit. *Clin Invest Med* 1992; **15(5)**:476-481. **C**
47. Hoffman A, Staempfli H, **Willan A**. Prognostic variables for survival of neonatal foals under intensive care. *J Vet Med* 1992; **6**:89-95. **C**
48. Warr D, **Willan A**, Venner P, Pater J, Kaizer L, Laberge F, Latreille J, Stewart D, O'Connell G, Osoba D, Wilson K, Davis A, Johnston D. A randomized, double-blind comparison of Granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for Cisplatin-induced emesis. *Eur J Cancer* 1993; **29A**:33-36. **CPA**
49. Cook D, Guyatt G, McIlroy W, Reeve B, **Willan A**, Pearl R. Serum Cortisol: A predictor of mortality in sepsis? *J Intens Care Med* 1993; **7**:84-89. **C**
50. Jaeschke R, Guyatt G, Cook D, Morris J, **Willan A**, McIlroy W, Harper S, Ramsdale H, Haddon R, Fitzgerald M, Newhouse M. The effect of increasing doses of β agonists on airflow in patients with chronic airflow limitation. *Respir Med* 1993; **87**:433-438. **C**
51. Cruess A, **Willan A**, Ballantyne M. Argon green versus krypton red laser photocoagulation for extrafoveal choroidal neovascularization: One-year results in age related macular degeneration. *Arch Ophthalmol* 1993; **111**:181-185. **CPA**
52. O'Brien BJ, Drummond MF, Labelle RJ, **Willan A**. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. *Med Care* 1993; **32(2)**:150-163. **C**
53. Cook D, Guyatt G, Ryan G, Clifton J, **Willan A**, McIlroy W, Oxman A. Publication bias in meta-analysis: current convictions and controversies. *J Amer Med Assoc* 1993; **269**:2749-2753. **C**
54. Guyatt G, Nishikawa J, **Willan A**, McIlroy W, Cook D, Gibson J, Kerigan A, Neville A. A measurement process for evaluating clinical teachers. *Can Med Assoc J* 1993; **149(8)**: 1097-1102. **C**

55. Molloy W, Guyatt G, Standish T, **Willan A**, McIlroy W, D'Souza J, Brown G, Mondadori C. Effect of a new onotropic agent, CGS 5469B on cognition, function and behaviour in Dementia. *J Gen Intern Med* 1993; 8(8):444-7. **C**
56. Cook D, Guyatt G, Davis C, **Willan A**, McIlroy W. A diagnostic and therapeutic N of 1 randomized trial. *Can J Psychiatry* 1993; **38**:251-254. **C**
57. Cook D, Juniper E, McIlroy W, **Willan A**, Jaeschke R, Guyatt G, Epstein R. Interviewer versus self-administered questionnaires in developing a disease-specific, health-related quality of life instrument for asthma. *J Clin Epidemiol* 1993; **46**:529-534. **C**
58. Guyatt G, Eagle J, Sackett B, **Willan A**, McIlroy W, Patterson C, Turpie I. Development and testing of a questionnaire to measure the quality of life in the frail elderly. *J Clin Epidemiol* 1993; **46**(12):1433-44. **C**
59. Haynes RB, Johnston ME, McKibbon KA, Walker CJ, **Willan A**. A program to enhance clinical use of Medline: A randomized controlled trial. *Cur Clin Trials* **1993**: Doc No 56. **C**
60. Collins J, Burrows E, **Willan A**. Occupation and the follow-up of infertile couples. *Fertil Steril* 1993; **60**:477-486. **C**
61. **Willan A**. Power function arguments in support of an alternative approach for analyzing management trials. *Control Clin Trials* 1994; **15**:211-219. **PA**
62. Juniper EF, Guyatt GH, **Willan A**, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. *J Clin Epidemiol* 1994; **47**:81-87. **C**
63. Haynes B, Walker C, McKibbon A, Johnson M, **Willan A**. Performance of 27 MEDLINE systems tested by searches on clinical questions. *J Amer Med Informatics Assoc* 1994; **1**:285-295. **C**
64. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJR, Roy P, Lacroix J, Griffith L, **Willan A**. Risk factors for gastrointestinal bleeding in critically ill patients. *N Engl J Med* 1994; **330**:377-381. **C**
65. Collins JA, Burrows EA, **Willan A**. Occupation and the clinical characteristics of infertile couples. *Can J Public Health* 1994; **85**:28-32. **C**
66. Juniper EF, Guyatt GH, **Willan A**, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. *Qual Life Res* 1994; **3**:43-48. **C**
67. Hillers TK, Guyatt GH, Oldridge N, Crowe J, **Willan A**, Griffith LE, Feeny D. Quality of life after myocardial infarction. *J Clin Epidemiol* 1994; **47**:1287-1296. **C**

68. Gilbert R, **Willan A**, Richardson S, Sellick S. Survey of family physicians: what is their role in cancer patient care? *Can J Oncol* 1994; **4**:285-290. **CPA**
69. Cruess A, **Willan A**, Ballantyne M. Argon green versus krypton red laser photocoagulation for extrafoveal choroidal neovascularization: One-year results in Ocular Histoplasmosis. *Arch Ophthalmol* 1994; **112**:1166-1173. **CPA**
70. Jaeschke R, Guyatt G, **Willan A**, Cook D, Harper S, Morris J, Ramsdale H, Haddon R, Newhouse M. Effect of increasing doses of beta-agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation. *Thorax* 1994; **49**:479-484. **C**
71. Kozousek V, Smith S, Gomolin J, Cruess Af, Henry T, Boucher M, Dumas J, Labelle P, Lalonde D, Mandelcorn M, Fischer M, Britton W, Desroches G, Leonard B, Currie C, Grant G, Plant J, Siebert L, Howcroft M, Shea M, Giavedoni L, Magyarosi M, Chew E, Ridley M, Moffat K, Devenyi R, Mezei S, Harvey P, Chisholm L, Kaus L, Canny C, Schneidmiller B, Gonder J, Hooper P, Hebrang M, **Willan AR**, Ballantyne M, Howitt C. Argon Green Vs Krypton Red Laser Photocoagulation For Extrafoveal Choroidal Neovascularization - One-Year Results In Ocular Histoplasmosis. *Arch Ophthalmol* 1994; **112**:1166-1173. **CPA**
72. Cook DJ, Guyatt G, Jaeschke R, Reeve J, Spanier A, King D, Molloy W, **Willan A**, Striener D. Determinants in Canadian health care workers of the decision to withdraw life support from the critically ill. *J Amer Med Assoc* 1995; **273**:703-708. **C**
73. Dawson S, Irwin L, Aaron E, **Willan A**, Barr RD. Minimizing blood loss in the use of indwelling central venous catheters in children with cancer. *Can J Med Technol* 1995; **57**:102-107. **C**
74. Collins J, Burrows E, **Willan A**. The prognosis for live birth among untreated infertile couples. *Fertil Steril* 1995; **64**:22-28. **C**
75. Levine MN, Gent M, Hirsh J, Weitz J, Turpie A, Powers P, Neemeh J, **Willan A**, Skingley P. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. *Arch Intern Med* 1996; **156**:851-856. **C**
76. Mitchell-DiCenso A, Guyatt G, Marrin M, Goeree R, **Willan A**, Southwell D, Hewson S, Paes B, Rosenbaum P, Hunsberger M, Baumann A. A controlled trial of nurse practitioners in neonatal intensive care. *Pediatrics* 1996; **98**:1143-1147. **C**
77. **Willan A**, Cruess AF, Ballantyne M. Argon green vs krypton red laser photocoagulation of extrafoveal choroidal Neovascular Lesions: Three-year results in age-related macular generation. *Can J Ophthalmol* 1996; **31**:11-17. **PA**

78. Savilo E, Harnish DG, deSa D, **Willan A**, Barr R. Comparison of the prognostic significance of the Shimada classification and N-myc copy number in neuroblastoma: A prospective study. *Int J Oncol* 1996; **8**:342-347. **C**
79. Mohide EA, Whelan T, Rath D, Gafni A, **Willan A**, Czukar D, Campbell I, Akawara G, Neimanis M, Levine M. A randomized trial to evaluate two information packages mailed to new patients prior to their initial appointment at a regional cancer centre. *Br J Cancer* 1996; **73**:1588-1593. **C**
80. Hannah M, Ohlsson A, Farine D, Hewson S, Hodnett E, Myhr T, Wang E, Weston J, **Willan A**. A comparison of induction of labor with expectant management for prelabor rupture of membranes at term. *N Engl J Med* 1996; **334**:1005-1010. **C**
81. Levine M, Gent M, Hirsh J, **Willan A**. A randomized trial of low molecular weight heparin administered primarily at home compared with in-hospital unfractionated heparin in the treatment of patients with proximal deep vein thrombosis. *N Engl J Med* 1996; **334**:677-681. **C**
82. **Willan A**, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: An application of Fieller's Theorem. *Health Economics* 1996; **5**:297-305. Addendum 1999; **8**(4). **PA**
83. Cook RJ, **Willan A**. Design considerations in crossover trials with a single interim analysis and serial patient entry. *Biometrics* 1996; **52**:732-739. **CPA**
84. Clark R, Whelan T, Levine M, Roberts R, **Willan A**, McCulloch P, Lipa M, Wilkinson R, Mahoney L. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. *J Nat Cancer Inst* 1996; **88**:1659-1664. **C**
85. Johnson M, Harrison L, Moffat K, **Willan A**, Hirsh J. Reliability of the INR for monitoring the induction phase of warfarin: Comparison with the prothrombin time ratio. *J Lab Clin Med* 1996; **128**:214-217. **C**
86. Belisle S, Collins J, Burrows E, **Willan A**. The value of laparoscopy among infertile women with tubal patency. *J Soc Obstet Gynecol Can* 1996; **18**:326-336. **C**
87. Mitchell-DiCenso A, Thomas H, Devlin C, Goldsmith C, **Willan A**, Singer J, Marks S, Watters D, Hewson S. Evaluation of an educational program to prevent adolescent pregnancy. *Health Ed Quart* 1997; **24**:300-312. **C**
88. Parkin P, Kirpalani H, Rosenbaum P, Fehlings D, Van Nie A, **Willan A**, King D. Development of a health-related quality of life instrument for use with children with spina bifida. *Qual Life Res* 1997; **6**:123-132. **C**

89. O'Brien B, Goeree R, Hunt R, Wilkinson J, Levine M, **Willan A**. Cost-effectiveness of alternative H. pylori eradication strategies in the management of duodenal ulcer. *Can J Gastroenterol* 1997; **11**(4):323-331. **C**
90. Hannah M, Ohlsson A, Wang E, Matlow A, Foster G, **Willan A**, Hodnett E, Weston J, Farine D, Seaward G. Maternal colonization with group B streptococcus and prelabor rupture of membranes at term: The role of induction of labor. *Amer J Obstet Gynaecol* 1997; **177**:780-785. **C**
91. **Willan A**, O'Brien BJ, Cook DJ. Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. *Control Clin Trials* 1997; **18**:121-130. **PA**
92. Gafni A, Goeree R, Myhr T, Hannah M, Blackhouse G, **Willan A**, Weston J, Wang E, Hodnett E, Hewson S, Farine D, Ohlsson A. Induction of labor compared with expectant management for prelabor rupture of the membrane at term: An economic evaluation. *Can Med Assoc J* 1997; **157**:1519-1525. **C**
93. Whelan T, Mohide A, **Willan A**. The supportive care needs of newly diagnosed patients attending a regional cancer center. *Cancer* 1997; **80**:1518-1524. **C**
94. Hodnett E, Hannah M, Weston J, Ohlsson A, Myhr T, Wong E, Hewson S, **Willan A**, Farine D. Women's evaluations of induction of labour versus expectant management for prelabour rupture of the membranes at term. *Birth* 1997; **24**:214-220. **C**
95. Barr RD, Halton J, **Willan A**, Cockshott WP, Gill G, Atkinson S. Impact of age and cranial Irradiation on radiographic skeletal pathology in children with acute lymphoblastic leukemia. *Med Pediat Oncol* 1998; **30**:347-350. **C**
96. Melnikow J, Nuovo J, **Willan A**, Chan B, Howell L. The natural history of cervical squamous intra-epithelial lesions: A meta-analysis. *Obstet Gynecol* 1998; **92**:727-735. **C**
97. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Warde P, **Willan AR**, Ernst S, Moore MJ, Neville A, Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian trial with palliative endpoints, *J Clin Oncol* 1998; **16**:2272-2279. **C**
98. Whelan TJ, Rath D, **Willan AR**, Neimanis M, Czukar D, Levine M. Evaluation of a patient file folder to improve dissemination of written informational materials for cancer patients. *Cancer* 1998; **83**:1620-1625. **C**
99. **Willan AR**, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. *Health Economics* 1999; **8**:203-211. **PA**
100. Whelan T, Levine M, Gafni A, Sanders K, **Willan AR**, Mirsky D, Schnider D, McCready D, Reid S, Kobylecky A, Reed K. Mastectomy or lumpectomy? Helping women make informed choices. *J Clin Oncol* 1999; **17**:1727-1735. **C**

101. O'Brien BJ, Levine M, **Willan AR**, Goeree R, Haley S, Blackhouse G, Gent M. Economic evaluation of outpatient treatment with low molecular weight heparin for proximal vein thrombosis. *Arch Intern Med* 1999; **159**:2298-2304. **C**
102. Peleg D, Hannah ME, Hodnett E, Foster G, **Willan A**, Farine D. Predictors of cesarean section after PROM at term. *Obstet Gynecol* 1999; **93**:1031-1035. **C**
103. Zaza C, Selleck SM, **Willan AR**, Reyno L, Browman GP. Health care professionals' familiarity with non-pharmacological strategies for managing cancer pain. *Psycho-Oncology* 1999; **8**:99-111. **C**
104. Goeree R, O'Brien B, Connolly S, Blackhouse G, **Willan AR**. Can we afford high technology medicine devices? The results from the Canadian implantable defibrillator study (CIDS) are shocking! *Med Decision Making* 1999; **19**(4):541. **C**
105. Agro K, Blackhouse G, Goeree R, **Willan AR**, Huang J-Q, Hunt R, O'Brien BJ. Cost-Effectiveness of Hp-PAC* for the Eradication of Helicobacter Pylori in the Management of Duodenal Ulcer in Canada. *Can J Gastroenterol* 1999; **13** (Suppl B): 151B. **C**
106. Goeree R, O'Brien B, Hunt R, Blackhouse G, Willan A, Watson J. Economic evaluation of long term management strategies for erosive oesophagitis. *Pharmacoeconomics* 1999; **16**:679-697. **C**
107. Guyatt GH, DiCenso A, Farewell V, **Willan AR**, Griffith L. Randomized trials versus observational studies in adolescent pregnancy prevention. *J Clin Epidemiol* 2000; **53**:167-174. **C**
108. O'Brien BJ, **Willan AR**, Blackhouse G, Goeree R, Cohen M, Goodman S. Is the use of low-molecular-weight heparin (Enoxaparin) in acute coronary syndrome patients cost saving in Canada? *Amer Heart J* 2000; **139**:423-429. **CPA**
109. Molloy DW, Guyatt GH, Jubelius R, Goeree R, O'Brien BJ, Bedard M, **Willan AR**, et al. Systematic implementation of an advanced directive program: a randomized trial in six nursing homes. *J Amer Med Assoc* 2000; **283**:1437-144. **C**
110. Siersted HC, Walker CM, O'Shaughnessy AD, **Willan AR**, Wiecek EM, Sears MR. Comparison of two standardised methods of methacholine inhalation challenge in young adults. *Eur Respir J* 2000; **15**:181-184. **C**
111. Hannah ME, Hodnett ED, **Willan AR**, Foster GA, Di Cecco R, Helewa M. Prelabor rupture of membranes at term: expectant management at home versus hospital. *Obstet Gynecol* 2000; **96**(4)533-538. **C**

112. Kirpalani HM, Parkin PC, **Willan AR**, Fehlings DL, Rosenbaum PL, King D, Van Nie AJ. Quality of life in spina bifida: importance of parental hope. *Arch Dis Child* 2000; **83**:293-297. **C**
113. Grunfeld E, Whelan TJ, Zitzelsberger L, **Willan AR**, Montesanto B, Evans WK. Cancer care workers in Ontario: prevalence of burnout, job stress and job satisfaction. *Can Med Assoc J* 2000;**163**:166-169. **C**
114. Hannah ME, Hannah, WJ, Hewson SA, Hodnett ED, Saigal S, **Willan AR**. Term Breech Trial: a multicentre international randomised controlled trial of planned caesarean section and planned vaginal birth for breech presentation at term. *The Lancet* 2000; **356**:1375-1383. **C**
115. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, **Willan AR**, Yee R, Roberts RS, Gent M. Cost-effectiveness, on the implantable cardioverter defibrillator results from the Canadian implantable defibrillator study (CIDS). *Circulation* 2000; **103**:1416-1421. **C**
116. Wilson K, Gibson N, **Willan A**, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. *Arch Intern Med.* 2000;**160**:939-44. **C**
117. Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, **Willan AR**, Pierce CH, Greenburg AG. A phase I study of oxidized raffinose cross-linked human hemoglobin. *Crit Care Med.* 2000; **28**:2283-92. **C**
118. Nuovo J, Melnikow J, **Willan AR**, Chan BKS. Treatment outcomes for squamous intraepithelial lesions. *Int J Gynec Obstet* 2000; **68**:25-33. **C**
119. Feldman B, Wang E, **Willan AR**, Szalai JP. The randomized placebo-phase design for clinical trials. *J Clin Epidemiol* 2001; **54**:550-557. **C**
120. **Willan AR**, Lin DY. Incremental net benefit in randomized clinical trials. *Stat Med.* 2001; **20**:1563-1574. **PA**
121. **Willan AR**, Analysis, sample size and power for estimating incremental net health benefit from clinical trial data. *Control Clin Trials.* 2001; **22**:228-237. **PA**
122. **Willan AR**, O'Brien BJ. Cost prediction models for the comparison of two groups. *Health Economics* 2001; **10**:363-366. **PA**
123. **Willan AR**, O'Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. *Stat Med* 2001; **20**:3251-3259. **PA**
124. Agro K, Blackhouse G, Goeree R, **Willan AR**, Huang J-Q, Hunt R, O'Brien BJ. Cost-effectiveness in Canada of a multidrug prepackaged regimen for *Helicobacter Pylori* eradication. *Pharmacoeconomics* 2001; **19**:831-843. **C**

125. **Willan AR.** On the probability of cost-effectiveness using data from randomized clinical trials. *BMC Med Res Meth* 2001;1:8. (www.biomedcentral.com/1471-2288/1/8/) **PA**
126. Hoch JS, Briggs AH, **Willan AR.** Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health Economics* 2002; **11**:415-430. **C**
127. Aghajafari F, Murphy K, **Willan AR,** Ohlsson A, Amankwah K, Matthews S, Hannah ME. Multiple courses of antenatal corticosteroids: A systematic review and meta-analysis. *Am J Ob Gyn* 2001;**185**:1073-1080. **C**
128. O'Brien BJ, Gertsen K, **Willan AR,** Faulkner L, Is there a kink in consumers' threshold value for cost-effectiveness in health care. *Health Economics* 2002; **11**:175-180. **C**
129. DiCenso A, Guyatt G, **Willan AR,** Griffith L. Interventions to reduce unintended pregnancies among adolescents: systematic review of randomised controlled trials. *BMJ* 2002; **324**:1426-1430. **C**
130. Hannah ME, Hannah WJ, Hodnett ED, Chalmers B, Kung R, **Willan A,** Amankwah K, Cheng M, Helewa M, Hewson S, Saigal S, Whyte H, Gafni A for the Term Breech Trial Collaborative Group. Outcomes at 3 months postpartum for women in the multicentre international randomised Term Breech Trial of planned caesarean section and planned vaginal birth for breech presentation at term. *JAMA* 2002; **287**(14):1822-1831. **C**
131. Guyatt G, Adachi J, Cranney A *et al.* Meta-Analyses of Therapies for Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; **23**(4):495-497. **C**
132. Cranney A, Tugwell P, Wells G *et al.* Systematic Reviews of Randomized Trials in Osteoporosis: Introduction and Methodology. *Endocrine Reviews* 2002; **23**(4):497-507. **C**
133. Cranney A, Wells G, **Willan AR et al.** Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women. *Endocrine Reviews* 2002; **23**(4):508-516. **C**
134. Cranney A, Tugwell P, Adachi J *et al.* Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; **23**(4):517-523. **C**
135. Cranney A, Tugwell P, Zytaruk N *et al.* Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; **23**(4):524-528. **C**
136. Wells G, Tugwell P, Shea B *et al.* Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women. *Endocrine Reviews* 2002; **23**(4):529-539. **C**

137. Cranney A, Tugwell P, Zytaruk N *et al.* Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; **23**(4):540-551. **C**
138. Shea B, Wells G, Cranney A *et al.* Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; **23**(4):552-559. **C**
139. Papadimitropoulos E, Wells G, Shea B *et al.* Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women. *Endocrine Reviews* 2002; **23**(4):560-569. **C**
140. Cranney A, Guyatt G, Griffith L *et al.* Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; **23**(4):570-578. **C**
141. Sears MR, Greene JM, **Willan AR**, Taylor DR, Flannery EM, Herbison GP, Poulton R. The long-term relationship between breast-feeding and development of atopy and asthma in children and young adults: a longitudinal study. *The Lancet* 2002; **360**:901-907. **CPA**
142. Hodnett ED, Lowe NK, Hannah ME, **Willan AR**, Stevens B, Weston JA, Ohlsson A, Gafni A, Muir HA, Myhr TL, Stremler R. The Effectiveness of Nurses as Providers of Labor Support in North American Hospitals. *JAMA* 2002; **288**:1373-1381. **C**
143. **Willan AR**, Lin DY, Cook RJ, Chen E. Using inverse-weighting in cost-effectiveness analysis with censored data. *Statistical Methods in Medical Research* 2002; **11**:539-551. **PA**
144. Browman GP, Mohide EA, **Willan AR**, Hodson I, Wong G, Grimard L, MacKenzie RG, El-Sayed S, Dunn E, Farrell S. Association Between Smoking During Radiotherapy and Prognosis in Head and Neck Cancer: A Follow-up Study. *Head and Neck* 2002; **24**:1031-1037. **C**
145. Douketis JD, Eikelboom JW, Quinlan DJ, **Willan AR**, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement - A meta-analysis of prospective studies investigating symptomatic outcomes. *Arch Int Med* 2002; **162**:1465-1471. **C**
146. Cosby RH, Howard M, Kaczorowski J, **Willan AR**, Sellors JW. Randomizing patients by family practice: sample size estimation, intracluster correlation, and data analysis. *Family Practice* 2003; **20**(1):77-82. **C**
147. **Willan AR**, Chen E, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with qualify-adjusted survival. *Statistics in Medicine* 2003; **22**:353-362. **PA**
148. Whelan T, Sawka C, Levine M, Gafni, Reyno L, **Willan AR**, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I. Helping patients making informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. *Journal of the National Cancer Institute* 2003; **95**:581-587. **C**

149. Sellors J, Kaczorowski J, Woodward C, **Willan AR**, Sellors C, Dolovich L, Goeree R, Cosby R, Trim K, Sebaldt R, Howard M, Poston J. Randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. *Can Med Assoc J* 2003; **169**:17-22. **C**
150. Sears MR, Greene JM, **Willan AR**, Wiecek, EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R. Persistence, remission and relapse of childhood asthma followed to adulthood: a longitudinal population-based cohort study. *NEJM* 2003; **349(15)**:1414-1422. **CPA**
151. Su M, McLeod L, Ross S, **Willan AR**, Hannah WJ, Hutton E, Hewson S, Hannah ME. Factors associated with perinatal or neonatal mortality of serious neonatal morbidity in the Term Breech Trial. *American Journal of Obstetrics and Gynecology* 2003; **189**:740-745. **C**
152. Charles CA, Whelan T, Gafni A, **Willan AR**, Farrell S. Shared treatment decision making: What does it mean to physicians? *J Clin Oncol* 2003; **21**:932-936. **C**
153. Crooks DL, Whelan TJ, Reyno L, **Willan AR**, Tozer R, Mings D, Miller J, Tew M, Elliott P, Levine M. The Initial Health Assessment: an intervention to identify the supportive care needs of cancer patients. *Support Cancer Care* 2004; **12**:19-24. **C**
154. Caetano M, Ornstein MP, von Dadelszen P, Hannah ME, Logan AG, Gruslin A, **Willan AR**, Magee LA. A survey of Canadian practitioners regarding the management of the hypertensive disorders of pregnancy. *Hypertension in Pregnancy* 2004; **23**: 61-74. **C**
155. Caetano M, Ornstein MP, von Dadelszen P, Hannah ME, Logan AG, Gruslin A, **Willan AR**, Magee LA. A survey of Canadian practitioners regarding diagnosis and evaluation of the hypertensive disorders of pregnancy. *Hypertension in Pregnancy* 2004; **23**:197-209. **C**
156. **Willan AR**. Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. *European Journal of Gastroenterology and Hepatology* 2004; **16**:543-549. **PA**
157. **Willan AR**, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. *Health Economics* 2004; **13**:461-475. **PA**
158. Akoury HA, Hannah ME, Chitayat C, Thomas M, Winsor E, Einarson R, Seaward G, Ryan G, Ferris LE, **Willan AR**, Windrim R. Randomized controlled trial of misoprostol for second trimester pregnancy termination associated with fetal malformation. *American Journal of Obstetrics and Gynecology* 2004; **190**:755-762. **C**

159. Wise MR, Shapiro H, Bodley J, Pittini R, McKay D, **Willan AR**, Hannah ME. Factors Affecting Academic Promotion in Obstetrics and Gynaecology in Canada. *Journal of Obstetrics and Gynaecology Canada* 2004; **26**:127-136. **C**
160. Chiba N, Gralnek IM, Moayyedi P, Provenzale D, Inadomi JM, **Willan AR**, Briggs AH, Kim WR. A glossary of economic terms. *Eur J Gastro Hepat* 2004; **16**:563-565. **C**
161. Grunfeld E, Coyle D, Whelan T, Clinch J, Reyno L, Earle CC, **Willan AR**, Viola R, Coristine M, Janz T, Glossop R. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. *CAMJ* 2004; **170**:1795-1801. **C**
162. **Willan AR**, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. *Statistics in Medicine* 2005; **24**:131-145. **PA**
163. Su M, Hannah WJ, **Willan AR**, Ross S, Hannah ME. Planned caesarean section decreases the risk of adverse perinatal outcome due to both labour and delivery complications in the Term Breech Trial. *BJOG: An International Journal of Obstetrics and Gynaecology* 2004; **111**:1065-1074. **C**
164. Whyte H, Hannah ME, Saigal S, Hannah WJ, Hewson S, Amankwah K, Cheng M, Gafni A, Helewa M, Hodnett EDD, Hutton E, Kung R, McKay D, Ross S, **Willan AR**. Outcomes of children at 2 years of age in the Term Breech Trial: a randomised controlled trial of planned caesarean versus planned vaginal birth for breech presentation at term. *American Journal of Obstetrics and Gynecology* 2004; **191**:864-871. **C**
165. Whelan T, Levine M, **Willan AR**, Gafni A, Sanders K, Mirsky D, Chambers S, O'Brien MA, Reid S, Dubois S. Empowering women and their Physicians with evidence. *JAMA* 2004; **292**:435-441. **C**
166. Hannah ME, Whyte H, Hannah WJ, Hewson S, Amankwah K, Cheng M, Gafni A, Helewa M, Hodnett ED, Hutton E, Kung R, McKay D, Ross S, Saigal S, **Willan AR**. Maternal outcomes at 2 years after planned cesarean vs planned vaginal delivery for breech presentation at term: the international randomized Term Breech Trial. *American Journal of Obstetrics and Gynaecology* 2004; **191**:917-927. **C**
167. Briggs AH, Buxton M, Drummond M, Goeree R, Sculpher MJ, **Willan AR**. Unfinished Symphony: A Tribute to the Life and Career of Bernie O'Brien (1959-2004). *Medical Decision Making* 2004; **24**:538-544. **CA**
168. **Willan AR**, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. *Health Economics* 2005; **14**:327-328. **PA**
169. **Willan AR**, Pinto EM. The expected value of information and optimal clinical trial design. *Statistics in Medicine* 2005; **24**:1791-1806. **PA**

170. Pinto EM, **Willan AR**, O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. *Statistics in Medicine* 2005; **24**:1965-1982. **SRA**
171. Hodnett ED, Hannah ME, Hewson S, Whyte H, Hannah Wj, Amankwah K, Cheng M, Gafni A, Guselle P, Helewa M, Eilen Hutton E, Kung R, Mckay D, Ross S, Saigal S, **Willan AR**. Mothers' views of their childbirth experiences two years after participation in the Term Breech Trial: an international randomized trial of planned caesarean versus planned vaginal birth for breech presentation at term. *Journal of Obstetrics and Gynaecology Canada* 2005; **27(3)**:224–231. **C**
172. O'Hagan A, McCabe C, Akehurst R, Brennan A, BriggsA, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, **Willan AR**. Incorporation of uncertainty in health economic modelling studies. *Pharmacoeconomics* 2005; **23(6)**: 529-36. **C**
173. Taylor DR, Cowan, JO, Greene JM, **Willan AR**, Sears MR. Asthma in remission: can relapse in early adulthood be predicted at age 18? *Chest* 2005; **127**: 845-850. **C**
174. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM, Tsiatis AA, **Willan AR**, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. *American Heart Journal* 2005; **149(3)**: 434-443. **C**
175. Howard AW, Macarthur C, **Willan AR**, Rothman L, Moses McKeag A, Macpherson A. Removal and Replacement of Play Equipment Not Meeting Standards Reduces Playground Injury Rates. *Can Med Assoc J* 2005; **172(11)**: 1443-1446. **C**
176. Stremler R, Hodnett E, Petryshen P, Stevens B, Weston J, and **Willan AR**. Randomized controlled trial of hands-and-knees positioning for occipitoposterior position in labor. *Birth* 2005; **32**: 243-251. **C**
177. **Willan AR**, Goeree, R, Pinto EM, McBurney C, Blackhouse G. Economic evaluation of rivastigmine in patients with parkinson's disease dementia. *Pharmacoeconomics* 2006; **24**: 93-106. **PA**
178. Palencia R, Gafni A, Hannah ME, Ross S, **Willan AR et al**. The costs of planned caesarean versus planned vaginal birth in the Term Breech Trial. *CMAJ* 2006; **174**: 1109-1113.
179. Sofronas M, Ichord RN, Fullerton HJ, Lynch JK, Massicotte MP, **Willan AR**, deVeber G. Pediatric stroke initiatives and preliminary studies: what is known and what is needed? *Pediatric Neurology* 2006; **34**: 439-445. **C**
180. **Willan AR**. Statistical analysis of cost-effectiveness data from randomized clinical trials. *Expert Rev. Phamacoeconomics Outcomes Res.* 2006; **6**: 337-346. **PA**

181. Manca A, **Willan AR**. Lost in translation”: accounting for between country differences in the analysis of multinational cost effectiveness data. *Pharmacoeconomics* 2006; **24**: 1101-1119. **C**
182. Stremler R, Hodnett E, Lee K, MacMillan S, Mill C, Ongcangco L, **Willan AR**. A behavioral-educational intervention to promote maternal and infant sleep: a pilot randomized, controlled trial. *Sleep* 2006; **29**(12): 1609-1615. **C**
183. McCarter, Furlong W, Whitton AC, Feeny D, DePauw S, **Willan AR**, Barr RD. Health status measurements at diagnosis as predictors of survival among adults with brain tumors. *J Clin Oncol* 2006; **24**:3636-3543. **C**
184. Eckermann S, **Willan AR**. Expected value of information and decision making in HTA. *Health Economics* 2007; **16**: 195-209. **CPA**
185. Pullenayegum EM, **Willan AR**. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data. *Statistics in Medicine* 2007; **26**:3274-3299. **SRA**
186. Dolovich L, Sabharwal M, Agro K, Foster G, Lee A, McCarthy L , **Willan AR**. The effect of pharmacist education on asthma treatment plans for simulated patients. *Pharmacy World & Science* 2007; **29**: 228-239. **C**
187. Magee LA, von Dadelszen P, *et al.*, **Willan AR**, Hannah ME. The control of hypertension in pregnancy study pilot trial. *British Journal of Obstetrics and Gynecology* 2007; **11**(4): 770-778. **C**
188. **Willan AR**. Clinical decision making and the expected value of information. *Clinical Trials* 2007; **4**(2): 279-285. **PA**
189. Hossain A, **Willan AR**. Approximate MLEs of the parameters of location-scale models under type II censoring. *Statistics* 2007; **41**(5): 385-394. **SRA**
190. Su M, McLeod L, Ross S, **Willan AR**, Hannah WJ, Hutton EK, Hewson SA, McKay D, Hannah ME. Factors associated with maternal morbidity in the Term Breech Trial. *Journal of Obstetrics and Gynaecology of Canada* 2007; **29**: 324-330. **C**
191. Boutis K, **Willan AR**, Babyn P, Narayanan UG, Alman B, Schuh S. A randomized, controlled trial of a removable brace versus casting in children with low-risk ankle fractures. *Pediatrics* 2007; **119**(6): e1256-e1263. **CPA**
192. Magee LA, *et al.* **Willan AR**. Women’s views of the experiences in the CHIPS (Control of Hypertension in Pregnancy Study) Pilot Trial. *Hypertension in Pregnancy* 2007; **26**: 371-387. **C**

193. Eckermann S, **Willan AR**. Time and EVSI wait for no patient. *Value in Health* 2008; **11**: 522-526. **CPA**
194. **Willan AR**, Kowgier ME. Cost-effectiveness Analysis of a Multinational RCT with a Binary Measure of Effectiveness and an Interacting Covariate. *Health Economics* 2008; **17**: 777-791. **PA**
195. Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, Van Hout BA, **Willan AR**, Feldman B. Recommendations for the reporting of economic evaluations of hemophilia prophylaxis: a nominal group consensus statement on behalf of the economics expert working group of the International Prophylaxis Study Group. *Haemophilia* 2008; **14**: 127-132. **C**
196. Eckermann S, **Willan AR**. The option value of delay in health technology assessment. *Medical Decision Making* 2008; **28**: 300-305. **CPA**
197. Eckermann S, Briggs A, **Willan AR**. Health technology assessment in the cost-disutility plane. *Medical Decision Making* 2008; **28**: 172-181. **C**
198. **Willan AR**, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. *Clinical Trials* 2008; **5**: 289-300. **PA**
199. Hodnett ED, Sremler R, **Willan AR**, *et al*. Effect on birth outcomes of a formalised approach to care in hospital labour assessment units: international, randomised controlled trial. *BMJ* 2008; **337**: a1021. **C**
200. **Willan AR**. Optimal sample size determinations from an industry perspective based on the expected value of information. *Clinical Trials* 2008; **5**: 587-594. **PA**
201. Murphy KE, Hannah ME, **Willan AR** *et al*. Multiple courses of antenatal corticosteroids for preterm birth study (MACS): a randomised controlled trial. *Lancet* 2008; **372**:2143-2151. **C**
202. Nagel K, **Willan AR**, Lappan J, Korz L, Buckley N, Barr RD. Pediatric oncology sedation trial (POST): A double-blind randomized study. *Pediatr Blood and Cancer* 2008; **51**:634-638. **C**
203. Eckermann S, **Willan AR**. Globally optimal trial design for local decision making. *Health Economics* 2009; **18**:203-216. **CPA**
204. Schuh S, **Willan AR**, Stephens D, Dick PT, Coates A. Can Montelukast Shorten Prednisolone Therapy in Children with Mild to Moderate Acute Asthma? A Randomized Controlled Trial. *Journal of Pediatrics* 2009; **155**:795-800. **C**

205. Howard AW, Macarthur C, Rothman L, **Willan AR**, Macpherson AK. School playground surfacing and arm fractures in children: a cluster randomized trial comparing sand to wood chip surfaces. *PLoS Med* **6(12)**: e1000195. doi:10.1371/journal.pmed.1000195. **C**
206. Eckermann S, Coory M, **Willan AR**. Indirect comparison: relative risk fallacies and odds solution. *Journal of Clinical Epidemiology* 2009; **62**:1031-1036. **C**
207. **Willan AR**, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. *Health Economics* 2010; **19**:549-561. **PA**
208. Eckermann S, Karnon J, **Willan AR**. The value of Value of Information: best informing research design and prioritization using current methods. *PharmacoEconomics* 2010; **28(9)**:699-709. **C**
209. Hossain A, Beyene J, **Willan AR**, Hu P. Approximate Likelihood ratio test for detecting differential expression in microarray data. *Computational Statistics and Data Analysis* 2009; **53(10)**: 3685-3695. **C**
210. Abrahamyan L, Beyene J, Feng JY, Chon Y, **Willan AR**, Schmeling H, Horneff G, Keystone EC, Feldman BM. Response times follow lognormal or gamma distribution in arthritis patients. *Journal of Clinical Epidemiology* 2010; **63(12)**: 1363-1369. **C**
211. Abrahamyan L, Li CS, Beyene J, **Willan AR**, Feldman BM. The impact of survival distributions on the power of randomized clinical trials. *Journal of Clinical Epidemiology* 2011; **64(3)**: 286-292. **C**
212. Boutis K, **Willan AR**, Babyn P, Goeree R, Howard A. A Randomized Controlled Trial of Cast Versus Splint In Children with Acceptably Angulated Wrist Fractures. *Canadian Medical Association Journal* 2010; **182(14)**: 1507-1512. **CPA**
213. Eckermann S, Coory M, **Willan AR**. Consistently estimating risk difference when translating evidence to jurisdiction of interest. *PharmacoEconomics* 2011; **29(2)**: 87-96. **C**
214. Asztalos EV, Murphy KE, Hannah ME, **Willan AR et al**. Multiple courses of antenatal corticosteroids for preterm birth study: 2-Year outcomes. *Pediatrics*. Published online 2010 Oct 18; DOI: 10.1542/peds.2010-0857. **C**
215. **Willan AR**. Sample size determination for cost-effectiveness trials. *PharmacoEconomics* 2011; **29(11)**:933-949. **PA**
216. Harris SB, Kapor J, Lank CN, **Willan AR**, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. *Canadian Family Physician* 2010; **56**:e418-e424. **C**
217. von Keyserlingk C, Boutis K, **Willan AR**, Hopkins R, Goeree R. Cost-Effectiveness Analysis of Cast Versus Splint In Children with Acceptably Angulated Wrist Fractures.

International Journal of Technology assessment in Health Care 2011; DOI:10.1017/S0266462311000067. **CPA**

218. Eckermann S, **Willan AR**. Presenting and summarizing cost and effect evidence to best inform inference and societal decision making when comparing multiple strategies. *PharmacoEconomics* 2011; **29**(7):563-577. **C**
219. Pullenayegum EM, **Willan AR**. Marginal models for censored longitudinal cost data: appropriate working variance matrices in inverse-probability-weighted GEEs can improve precision. *International Journal of Biostatistics* 2011; **7**(1); www.bepress.com/ijb/vol7/iss1/14. **SRA**
220. **Willan AR**, Eckermann S. Expected value of information and pricing new health care interventions. *PharmacoEconomics* 2011; **29**(). **PA**
221. **Willan AR**, Eckermann S. Accounting for between-study variation in value of information methodology. *Health Economics* DOI: 10.1002/hec.1781. **PA**
222. Ballantyne M, Stevens B, Guttman A, **Willan AR**, Rosenbaum, P. Transition to neonatal follow-up programs – is attendance a problem? *Journal of Perinatal and Neonatal Nursing* (accepted for publication). **C**
223. Freedman SB, Parkin PC, **Willan AR**, Schuh S. Rapid versus standard intravenous rehydration in paediatric gastroenteritis: pragmatic blinded randomised clinical trial. *BMJ* 2011; **343**: bmj.d6976. **C**
224. Ungar WJ, Boydell K, Dell S, Feldman BM, Marshall D, **Willan AR**, Wright J. A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma. *PharmacoEconomics* 2012: (in press). **C**
225. Murphy KE, Hannah ME, **Willan AR et al**. Maternal Side-effects after multiple courses of antenatal corticosteroids (MACS): The three-month follow-up of women in the randomized controlled trial of MACS for preterm birth study. *J Obstet Gynaecol Can* 2011; **33**(9):909–921.

Books

Willan AR, Briggs AH. *The Statistical Analysis of Cost-effectiveness Data*. Chichester UK: Wiley 2006. **PA**

Contributions to Books

1. **Willan AR**, Warr D, Pater J, Levitt M, Erlichman C, Osoba D. Methodological issues in antiemetic studies. In *Effect of Cancer on Quality of Life*. Osoba D (ed). CRC Press 1991. **PA**
2. O'Brien B, Goeree R, Hunt R, Wilkinson J, Levine M, **Willan AR**, Economic evaluation of *Helicobacter pylori* eradication in the management of duodenal ulcer. In *Helicobacter pylori: Basic Mechanisms to Clinical Cure*. Kluwer Academic Publishers 1996. **C**
3. **Willan AR**. Analysing cost-effectiveness trials: net benefits. In *Statistical Methods for Cost-Effectiveness Research: A Guide to Current Issues and Future Developments*. Briggs AH (ed). London: Office of Health Economics 2003. **PA**
4. **Willan AR**. The use of value of information methods in the design and evaluation of clinical trials. In *Economic Evaluation in Child Health*. Ungar WJ. (ed). Oxford University Press 2010. **PA**

Journal Articles Submitted

(**PA**—Principal Author; **CPA**—Co-principal Author; **SRA**—Senior Responsible Author; **C**—Coauthor) (Research trainees underlined)

Murphy KE, **Willan AR**, Hannah ME *et al*. Do antenatal corticosteroids reduce fetal growth or gestational age at birth? *Obstetrics & Gynecology*. **C**

Willan AR, Boutis K, Goeree R. Applying value of information methods in the evaluation of research evidence. *Journal of Clinical Epidemiology*. **PA**

Chen MH, **Willan AR**. Determining optimal sample sizes for multistage randomized clinical trials from an industry perspective using value of information methods. *Clinical Trials*. **SRA**

Atenafu EG, Hamid JS, To T, **Willan AR**, Feldman BM and Beyene J. Bias corrected estimator for the ICC: Bias Corrected Estimator for Intraclass Correlation Coefficient. *BMC Medical Research Methodology*. **C**

Hossain A, **Willan AR**, Beyene J. A Flexible Nonparametric Approach to Find Candidate Genes Associated to Disease in Microarray experiments. *Journal of Bioinformatics and Computational Biology*. **C**

Hossain A, **Willan AR**, Beyene J. An improved method on Wilcoxon rank sum test for gene selection from microarray experiments. *Communications in Statistics*. **C**

Presentations

(Presenter underlined)

1. Willan A. Relative Efficiency in the Analysis of Survival Data. Annual meeting of The Society for Clinical Trials, Pittsburgh PA, May 1982.
2. Willan A, Pater J. The Mixed Benefits of Subtracting Baseline Measurements in Crossover Trials. Annual Meeting of the Canadian Society for Clinical Investigation, Calgary AB, September 1983.
3. Bow E, Pater J, **Willan A**. The Impact of Trimethoprim/Sulfamethoxazole for Infection Prophylaxis on the outcome of Empiric Antibiotic Therapy in Febrile Granulocytopenic Patients with Cancer. Annual Meeting of the American Society of Clinical Oncology, Toronto ON, May 1984.
4. Willan A, Pater J. Carryover and the Two-Period Crossover Clinical Trial. Annual Meeting of American Statistical Association, Philadelphia PA, August 1984.
5. Pater J, Shelley W, **Willan A**. The Effect of Histologic Subtypes, Grade and Residual Tumour Diameter on Survival and Negative Second Look Rates in Patients with Stage III or IV carcinoma of the Ovary. Annual Meeting of the American Society of Clinical Oncology, Toronto ON, May 1984.
6. Willan A, Pater J. Using Baseline Measurements to eliminate Carryover in the Two-Period Crossover Clinical Trial. The XIIth International Biometrics Conference, Tokyo, Japan, September 1984.
7. Osoba D, Erlichman C, **Willan A**. Superiority of Methylprednisolone Sodium Succinate over Conventional Dose Metoclopramide Hydrochloride the Prevention of Nausea and Vomiting Produced by Cancer Chemotherapy. Annual Meeting of American Society of Clinical Oncology, Houston TX, May 1985.
8. Willan A. Choosing The Largest Test Statistic in the Two-Period Crossover Trial. Annual Meeting of the American Statistical Association, Las Vegas NV, August 1985.
9. Pater J, **Willan A**, Erlichman C. A Validation of Self-reported Measures of Nausea and Vomiting. Annual Meeting of The Canadian Society for Clinical Investigation, Vancouver BC, September 1985.
10. Wallenstein S, Patel H, **Willan A**. Use of Baseline Values in the Two Period Two Treatment Crossover Design. Annual meeting of The Biometric Society (ENAR), Atlanta GA, March 1986.

11. Rapp E, Pater J, **Willan A**. A Comparison of Best Supportive Care to Two Regimens of Combination Chemotherapy in the Management of Advanced Non-Small Cell Lung Cancer. Annual meeting of the American Society of Clinical Oncology, Atlanta GA, May 1987.
12. Hoffman A, Staempfli H, **Willan A**. Survival Characteristics of Foals Hospitalized at Less Than Ten Days of Age: A Retrospective Analysis of Fifty-six Cases. Orlando FL, January 1988.
13. The Canadian Ophthalmology Study Group. The Effect of Laser Treatment Adequacy on Early Persistence/Recurrence of Choroidal Neovascularization. The Association for Research in Vision and Ophthalmology, Sarasota FL, May 1988, Cruess A presenting.
14. **Willan A**, Ross W, MacKenzie T. Comparison of in-patient classification systems: A problem of non-nested regression models. The American Statistical Association, New Orleans LA, August 1988.
15. **Willan A**, MacKenzie T. The statistical comparison of the utility of diagnostic tests. The American Statistical Association, Washington DC, August 1989.
16. Warr D, **Willan A**, Fine S. A double blind randomized comparison of the novel antiemetic BRL 43694A (Granisetron) versus Dexamethasone plus Prochlorperazine. European Conference of Clinical Oncology, London, England, September 1989.
17. Ballantyne M, **Willan A**, Cruess A. A controlled clinical trial in ophthalmology: Formal randomization may not be ethical. Society for Clinical Trials, Philadelphia PA, May 1992.
18. Cruess A, **Willan A**, Ballantyne M. Argon green versus krypton red laser photocoagulation for extrafoveal choroidal neovascularization. Association for Research in Vision and Ophthalmology, Sarasota FL, May 1992.
19. Cruess A, **Willan A**, Ballantyne M. Argon green versus krypton red laser photocoagulation: Persistence and recurrence of CNVM in AMD. American Academy of Ophthalmology, Dallas TX, 1992.
20. Rosenbaum P, Law M, Gowland C, King G, **Willan A**, Russell D, King S. Neurodevelopmental Clinical Research Unit. American Academy for Cerebral Palsy and Developmental Medicine, San Diego CA, 1992.
21. King S, Rosenbaum P, King G, Murfin L, **Willan A**. Practical and methodological strategies in developing a measure of the processes of caregiving. American Academy for Cerebral Palsy and Developmental Medicine, San Diego CA, 1992.
22. Neurodevelopmental Clinical Research Unit. Clinical measures of motor function and quality of movement. American Academy for Cerebral Palsy and Developmental Medicine, San Diego CA, 1992.

23. Kirpalani H, Parkin P, VanNie A, Fehlings D, **Willan A**, Rosenbaum P. Measurement of quality of life in patients with spina bifida. American Pediatric Society, Washington DC, May 1993.
24. Hewson S, **Willan A**, Hannah M. Issues around the release of a dataset from a completed clinical trial. Society for Clinical Trials, Houston TX, May 1994.
25. **Willan A**, O'Brien B. Cost-effectiveness ratios in health care: From deterministic to stochastic models. American Statistical Association, Toronto ON, August 1994.
26. Cruess A, **Willan A**, Ballantyne M. Argon green versus krypton red laser photocoagulation for extrafoveal choroidal neovascularization: 3 year POHS results. Association for Research in Vision and Ophthalmology, Ft. Lauderdale FL, May 1995.
27. **Willan A**, O'Brien B, Cook D. Benefit-risk ratios in the assessment of clinical evidence of a new therapy. Society for Clinical Trials, Seattle WA, May 1995, and Biometrics Society, Stanford CA, June 1995.
28. **Willan A**, O'Brien B, Cook D. Benefit-risk ratios in the assessment of clinical evidence of a new therapy. Statistical Society of Canada, invited talk, Waterloo ON, June 1996.
29. Zaza C, Sellick S, Reyno L, **Willan A**, Malik S, Charles K, Browman G. Cancer centre staff's familiarity with non-pharmacologic pain management techniques. World Congress of Psycho-Oncology, New York NY, October, 1996.
30. Seaward G, Hannah M, Myhr T, **Willan A**. PROM at term: Maternal risk factors for postpartum fever. Society of Perinatal Obstetricians, Anaheim CA, January 1997.
31. Seaward G, Hannah M, Myhr T, **Willan A**. PROM at term: Maternal risk factors for neonatal infection. Society of Perinatal Obstetricians, Anaheim CA, January 1997.
32. Seaward G, Hannah M, Myhr T, **Willan A**. PROM at term: Maternal risk factors for clinical chorioamnionitis. Society of Perinatal Obstetricians, Anaheim CA, January 1997.
33. Hannah M, Ohlsson A, Wang E, Myhr T, **Willan A**. Inducing labour with IV oxytocin may reduce the risk of neonatal infection in GBS positive women with PROM at term. Society of Perinatal Obstetricians, Anaheim CA, January 1997.
34. Gafni A, Goeree R, Myhr T, Hannah M, **Willan A**. Induction of labour compared with expectant management for PROM at term: An economic evaluation. Society of Perinatal Obstetricians, Anaheim CA, January 1997.
35. Hannah M, **Willan A** *et al.* Term breech trial: An RCT of planned caesarean section vs planned vaginal birth for breech at term. Society of Obstetricians and Gynaecologists of Canada, Halifax NS, June 1997.

36. Sellors J, Kaczorowski J, Woodward C, **Willan A**, *et al.* Seniors Medication Assessment Research Trial (SMART): A cluster randomized trial of expanded role pharmacists consulting to family physicians. North American Primary Care Research Group, Amelia Island FL, November 2000.
37. Cosby R, Kaczorowski J, **Willan A**, Sellors J. Statistical approach to sample size estimation and analysis in a community-based cluster randomized control trial: the Seniors Medication Assessment Research Trial (SMART) experience. North American Primary Care Research Group, Amelia Island FL, November 2000.
38. Sears M, Greene J, **Willan AR** *et al.* The Effect of Breastfeeding on the Risk of Atopy and Asthma: A Longitudinal Cohort Analysis. American Academy of Asthma, Allergy and Immunology, New Orleans LA, March 2001.
39. Sellors J, Kaczorowski J, Woodward C, **Willan A**. *et al.* Linking family physicians and expanded role pharmacists to optimize drug therapies. Canadian Association for Populations Therapeutics, Banff, AB, April 2001.
40. Lamda Dinsha B, **Willan A**, Hannah M. Generalizability Issues in a large multi-centre RCT. Society for Clinical Trials, Denver CO, May 2001.
41. Hewson S, Hannah M, Lamda Dinsha B, Weston, J, **Willan A**. Stopping a Trial Early: Implications for the DCC and Participating Sites. Society for Clinical Trials, Denver CO, May 2001.
42. Kaczorowski J, Sellors J, Sellors C, Woodward C, **Willan A**, Dolovich L. Seniors medication assessment research trial (Smart): a cluster randomized trial of expanded role pharmacists Consulting to family physicians. World Organisation of Family Doctors (WONCA), May 2001, Durban, South Africa.
43. Coyle D, Grunfeld E, Whelan T, **Willan A**, Reyno L, Earle C, Cristine M, Stonebridge C, Christie A. Financial Burden on Patients and Family Caregivers due to Advanced Breast Cancer. Canadian Breast Cancer Research Initiative Conference, Quebec City, PQ, May 2001.
44. Dolovich LR, Agro K, Sabharwal M, Foster G, Lee A, **Willan A**, Tsao S. A comparison of self reported learning with objective assessment of community pharmacists receiving asthma education. American Thoracic Society, San Francisco, CA, May 2001.
45. Hoch J, **Willan A**, Briggs A. Something old, something new, something borrowed, something BLUE: A framework for the marriage of health econometrics and cost-effectiveness analysis. iHEA, York, UK, July, 2001.

46. O'Brien BJ, Blackhouse G, **Willan AR**. Analysis of uncertainty when cost and effect data from a trial are subject to censoring: the case of implantable defibrillators. iHEA, York, UK, July 2001.
47. Akoury H, Einerson T, Hannah M, Chitayat D, Seaward G, Winsor E, Windrim R, **Willan A**, Ferris L. Outcomes at 3 months postpartum for women enrolled in the Multicentre International Term Breech Trial of planned caesarean section and planned vaginal birth for breech presentation at term. Society for Maternal Fetal Medicine Annual Meeting, New Orleans LA, January 14-19, 2002.
48. Sellors J, Sellors C, Kaczorowski J, Woodward C, Dolovich L, **Willan A**, Goeree R, Trim K, Cosby R, Howard M, Sebaldt R, Poston J. Seniors Medication Assessment Research Trial (SMART): A cluster of randomized trials of expended role pharmacists consulting to family physicians. American Pharmaceutical Association Annual Meeting, Philadelphia PA, March 2002.
49. **Willan AR**. Sample size and power in cost-effectiveness analysis. Hospital for Sick Children, Toronto ON, April 2002.
50. Grunfeld E, Whelan T, Reyno L, Earle C, **Willan A**, Coyle D, Foster G. Health Service Utilization in Advanced Breast Cancer: Frequency and Predictors of Unplanned Acute Care Encounters (UACEs). American Society for Clinical Oncology Annual Meeting, Orlando FL, May 18-21, 2002.
51. O'Brien MA, Whelan TJ, Villasis-Keever M, Robinson P, Skye A, Gafni A, Brouwers M, Charles C, Baldassarre F, Gauld M, **Willan A**. Impact of Cancer-related Decision Aids: A Systematic Review. American Society for Clinical Oncology Annual Meeting, Orlando FL, May 18-21, 2002.
52. Grunfeld E, Whelan T, Reyno L, Earle C, **Willan AR**, Coyle D, Coristine M, Foster G. Sources of Supportive Care for Women with Advanced Breast Cancer. Supportive Care in Cancer Symposium, Boston MA, June 23-26, 2002.
53. **Willan AR**. An alternative approach for analyzing management trials. Hospital for Sick Children, Toronto ON, September 2002.
54. Grunfeld E, Whelan T, Reyno L, Earle C, **Willan AR**, Coyle D, Coristine M, Foster G. Use of health services and supportive care services by women with advanced breast cancer towards the end of life: results of a longitudinal study. International Conference in Palliative Care, Montreal QC, October 9, 2002.
55. Su M, McLeod L, Ross S, **Willan AR**, Hannah WJ, Hutton E, Hannah M for the TBT Collaborative Group. Factors associated with adverse perinatal outcome in the Term Breech Trial. SMFM, San Francisco, February 3-8, 2003. Am J Obstet Gynecol 2002;187:S69 (#41).

56. McLeod L, Su M, Ross S, Hannah WJ, **Willan AR**, Hutton E, Hannah M for the TBT Collaborative Group. Predictors of maternal mortality or serious maternal morbidity in the Term Breech Trial. SMFM, San Francisco, February 3-8, 2003. Am J Obstet Gynecol 2002;187:S100 (#142).
57. Kaczorowski J, Sellors J, Sellors C, Dolovich L, Howard M, Goeree R, Blackhouse G, Woodward C, **Willan AR**. Randomized trial of a pharmacist consultation program for family physicians and the elderly patients: 17 month follow-up. CAPT Meeting, Quebec, PQ, April 2003.
58. **Willan AR**, Briggs AH, Hoch JS. Covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. iHEA Annual Meeting, San Francisco, CA, June 2003.
59. Whelan T, Levine M, Gafni A, **Willan AR**, Sanders K, Mirsky D, Chambers S, O'Brien MA, Dubois S, Reid S. Empowering women and their physicians with the evidence: a randomized trial of a decision board for breast cancer surgery. International Shared Decision Making Conference, Swansea, UK, September 2003.
60. **Willan AR**. The expected value of information and the absurdity of traditional clinical trial design. Hospital for Sick Children, Toronto ON, November 2003.
61. Whyte H, Hannah ME, Saigal S, *et al*. Outcomes of children at 2 years of age in the Term Breech Trial, Society of Maternal and Fetal Medicine, New Orleans, February 2004.
62. Hannah ME, Whyte H, Hannah W, *et al*. Maternal outcomes at 2 years postpartum in the Term Breech Trial, Society of Maternal and Fetal Medicine, New Orleans, February 2004.
63. Cellors C, Kaczorowski J, *et al*. Randomized trial of a pharmacist consultation program for family physicians and their elderly patients: 17 month follow-up, American Pharmacists Association Conference, Seattle, March 2004.
64. **Willan AR**. The expected value of information and optimal clinical trial design. Society for Clinical Trials Meeting, New Orleans, LA, May 2004.
65. **Willan AR**. The expected value of information and optimal clinical trial design. Statistics in Health Sciences Conference, Nantes, France, June 2004.
66. **Willan AR**. Statistical cost-effectiveness analysis: incremental net benefit. Joint Statistical Meetings, Toronto, Canada, August 2004. (Invited)
67. **Willan AR**, Pinto. The expected value of information and optimal clinical trial design. ENAR Biometrics Society, Austin TX, March 2005.
68. Furlong W, McCarter H, Whitton AC, Feeny D, DePauw S, **Willan AR**, Barr RD. Health status measures as predictors of mortality among adults with brain tumors. International

- Society for Pharmacoeconomics and Outcomes Research Meeting, Philadelphia, PA, May 2006.
69. Palencia R, Gafni A, Hannah ME, Ross S, **Willan AR** *et al.* The costs of planned caesarean section versus planned vaginal birth in the term breech trial. SOGC, Vancouver BC, June 2006.
 70. Magee L, *et al.* The Chips Pilot Trial (Control of Hypertension In Pregnancy Study). SOGC, Vancouver BC, June 2006 and ISSHP, Lisbon, July 2006.
 71. **Willan AR**, Kowgier ME. Interim analysis for trials designed using the expected value of information. International Biometric Society Meetings, Montreal, PQ, July 2006.
 72. Eckermann S, **Willan AR**. Value of research to decision makers – optimal research design conditional on decision context. Health Technology Assessment International. Adelaide, Australia, July 2006.
 73. **Willan AR**, Kowgier ME. Interim analysis for trials designed using the expected value of information. International Clinical Biostatistics Society Meetings, Geneva, Switzerland, August 2006.
 74. International Paediatric Stroke Study Group. Establishing a Multinational Research Network in Paediatric Stroke: The International Paediatric Stroke Study Group. CNS, Pittsburgh PA, October 2006.
 75. International Paediatric Stroke Study Group. The Importance of Arteriopathy in Arterial Ischemic Stroke in Children: Results from the International Paediatric Stroke Study. CNS, Pittsburgh PA, October 2006.
 76. Eckermann S, **Willan AR**. The global value of information: optimal trial design and decision making across jurisdictions. iHEA, Copenhagen, July 2007.
 77. **Willan AR**, Eckermann S. Optimal decision making and trial design within jurisdiction. iHEA, Copenhagen, July 2007.
 78. Sculpher MJ, Lynd LD, **Willan AR**. First steps in developing a risk-benefit analysis framework: a systematic review and critical evaluation of risk-benefit analysis methods. iHEA, Copenhagen, July 2007.
 79. Eckermann S, **Willan AR**. Expected value of information and decision making in HTA. iHEA, Copenhagen, July 2007.
 80. Ungar WJ, Boydell K, Dell S, Feldman BM, Marshall DA, **Willan AR**, Wright J. The validity and reliability of a parent-child dyad approach to utility and quality-of-life assessment in children. ISPOR, Toronto, May 2008.

81. **Willan AR.** Using value of information methodology to determine the sample size for a randomized clinical trial from an industry perspective. ISPOR, Toronto, May 2008.
82. **Boutis K, Willan AR, Babyn P, Georee R, Howard A.** A randomised controlled trial of cast versus wrist splint in children with acceptably angulated wrist fractures. Canadian Orthopaedic Association Annual Meeting, Edmonton, June, 2010.

Invited Presentations and Workshops

1. **Willan AR.** Two-Period Crossovers: A Prescription for Use. Annual Meeting of the Biometric Society, ENAR, Boston MA, March 1988.
2. **Willan AR.** Using Fieller's theorem to estimate confidence intervals for cost-effectiveness ratios. Drug Information Association, New Orleans, LA, November 1997.
3. **Willan AR.** Cost-effectiveness assessment in clinical trials: issues related to statistical analysis and power. Drug Information Association, Hilton Head, SC, November 1998.
4. **Willan AR.** Incremental net benefit in clinical trials: issues related to statistical analysis and power. Drug Information Association, Orlando FL, November 1999.
5. **Willan AR.** The statistical analysis of cost-effectiveness data from clinical trials. American Public Health Association, Boston, MA, November 2000.
6. **Willan AR.** Censored Data and Incremental net benefit in clinical trials: issues related to statistical analysis and power. Drug Information Association, London, UK, February 2001.
7. **Willan AR.** Censored Data and Incremental net benefit in clinical trials: issues related to statistical analysis. Health Economics Research Centre, Oxford, UK, February 2001.
8. **Willan AR.** Incremental net benefit in randomized clinical trials. Joint Statistical Meetings, Atlanta, GA, August 2001.
9. **Willan AR.** Censored data in cost-effectiveness studies: two approaches. Health Economics Research Centre, Oxford, UK, December 2001.
10. **Willan AR.** Cost-effectiveness analysis when the WTA is greater than the WTP. Health Economics Research Centre, Oxford, UK, December 2001.
11. **Willan AR, O'Brien BJ, Leyva RA.** Cost-effectiveness analysis when the WTA is greater than the WTP. ENAR Biometrics Society, Arlington VA, March 2002.
12. **Willan AR.** Regression methods for censored cost-effectiveness data. Health Economics Research Centre, Oxford, UK, November 2002.

13. **Willan AR.** Economic evaluation methods: the statistician's viewpoint. Development of Economic Evaluation Methods, Bristol, UK, September 2003.
14. **Willan AR.** Statistical issues in Health Economics. ICES, Toronto ON, October 2003.
15. **Willan AR,** Lin DY, Chen EB, Cook RJ. Estimation in the presence of censoring in cost-effectiveness analyses. International Conference on Health Policy Research, Chicago IL, October 2003.
16. **Willan AR.** The expected value of information and optimal clinical trial design. Health Economics Research Centre, University of Oxford, UK, March 2004.
17. **Willan AR.** The expected value of information and optimal clinical trial design. Medical Statistics Unit, London School of Hygiene and Tropical Medicine, UK, March 2004.
18. **Willan AR.** The expected value of information and optimal clinical trial design. MRC Biostatistics Unit, University of Cambridge, UK, March 2004.
19. **Willan AR.** The expected value of information and optimal clinical trial design. Centre for Health Economics, University of York, UK, March 2004.
20. **Willan AR,** Pinto EM. Shrinkage estimators for individual countries in Multinational Cost-effectiveness RCTs. International Society for Pharmacoeconomics and Outcomes Research Meeting, Arlington VA, May 2004.
21. **Willan AR,** The statistical analysis of cost-effectiveness data from randomized clinical trials I. NHMRC CTC, University of Sydney, Sydney NSW, April 2005.
22. **Willan AR,** The statistical analysis of cost-effectiveness data from randomized clinical trials II. NHMRC CTC, University of Sydney, Sydney NSW, April 2005.
23. **Willan AR.** The expected value of information and optimal clinical trial design. NHMRC CTC, University of Sydney, Sydney NSW, April 2005.
24. **Willan AR,** The statistical analysis of cost-effectiveness data from randomized clinical trials I. Centre for Health Economics, Monash University, Melbourne VIC, April 2005.
25. **Willan AR,** The statistical analysis of cost-effectiveness data from randomized clinical trials II. Centre for Health Economics, Monash University, Melbourne VIC, April 2005.
26. **Willan AR.** The expected value of information and optimal clinical trial design. Centre for Health Economics, Monash University, Melbourne VIC, April 2005.
27. **Willan AR,** Pinto EM. Shrinkage estimation in the cost-effectiveness analysis of multinational clinical trials. iHEA World Congress, Barcelona, Spain, July 2005.

28. **Willan AR.** Statistical approaches for benefit-harm analysis. Joint Statistical Meetings, Minneapolis, MN, August 2005.
29. **Willan AR,** Lin DY, Manca A. Covariate adjustment in cost-effectiveness analysis with censored data. ENAR Biometrics Society, Tampa FL, March 2006.
30. **Willan AR,** Eckermann S, Fenwick E. Workshop in Cost-effectiveness Analysis. The Pharmacy Benefits Advisory Committee of Australia, Sydney, November 2006.
31. **Willan AR.** Using the expected value of information for sample size determination and assessing clinical trial results. School of Public Health, University of Sydney. November, 2006.
32. **Willan AR.** Statistical analysis of cost-effectiveness data from clinical trials. Workshop on Health Economics from Theory to Practice. Sponsored by Flinders University, McLaren Vale, December, 2006.
33. **Willan AR.** The value of information to decision makers and principles for efficient trial design. Workshop on Health Economics from Theory to Practice. Sponsored by Flinders University, McLaren Vale, December, 2006.
34. **Willan AR.** Bayesian adaptive designs and EVI. Workshop on Health Economics from Theory to Practice. Sponsored by Flinders University, McLaren Vale, December, 2006.
35. **Willan AR.** Relaxing the Assumptions: EVI gets real. Workshop on Health Economics from Theory to Practice. Sponsored by Flinders University, McLaren Vale, December, 2006.
36. **Willan AR.** The Value of information to decision makers and principles of efficient trial design. Li Ka Shing Knowledge Institute, St Michael's Hospital, September, 2007.
37. **Willan AR.** Statistical Analysis of Cost-effectiveness Data From Clinical Trials. Workshop on Health Economics: from Theory to Practice. McLaren Vale, South Australia, December 2007.
38. **Willan AR.** The Value of Information and Principles for Efficient Trial Design. Workshop on Health Economics: from Theory to Practice. McLaren Vale, South Australia, December 2007.
39. **Willan AR.** Bayesian Adaptive Designs and EVI. Workshop on Health Economics: from Theory to Practice. McLaren Vale, South Australia, December 2007.
40. **Willan AR.** Relaxing the Assumptions: EVI Gets Real. Workshop on Health Economics: from Theory to Practice. McLaren Vale, South Australia, December 2007.
41. **Willan AR.** Mentoring and collaboration in medical research. Statistical Society of Canada, May 2008.

42. **Willan AR.** Statistical analysis of cost-effectiveness data from clinical trials. Workshop on Health Economics from Theory to Practice, Lyndoch Hill Retreat, South Australia, December 2008.
43. **Willan AR.** The value of information to decision makers and principles for efficient trial design. Workshop on Health Economics from Theory to Practice, Lyndoch Hill Retreat, South Australia, December 2008.
44. **Willan AR.** Bayesian adaptive designs and EVI. Workshop on Health Economics from Theory to Practice, Lyndoch Hill Retreat, South Australia, December 2008.
45. **Willan AR.** Relaxing the assumptions: VOI gets real. Workshop on Health Economics from Theory to Practice, Lyndoch Hill Retreat, South Australia, December 2008.
46. **Willan AR.** Optimal trial design from an industry perspective. Workshop on Health Economics from Theory to Practice, Lyndoch Hill Retreat, South Australia, December 2008.
47. **Willan AR, Eckermann S.** Optimal clinical trial design using value of information methods with imperfect implementation. International Health Economics Association, Beijing, July 2009.
48. **Willan AR.** The use of value of information methods in the design and evaluation of clinical trials. International Health Economics Association, Beijing, July 2009.
49. **Willan AR.** Why a Bayesian Be? University of Wollongong, February 2010.
50. **Willan AR.** The value of information and the pricing of new health interventions. University of Wollongong, February 2010.
51. **Willan AR.** Why a Bayesian Be? SORA/TABA Workshop, Toronto ON, May 2010.
52. **Willan AR.** Why a Bayesian Be? University of Aberdeen, June 2010.
53. **Willan AR.** The value of information and the pricing of new health interventions. University of Aberdeen, June 2010.
54. **Willan AR.** The value of information and the pricing of new health interventions. Quality Improvement Scotland, National Health Service, June 2010.
55. **Willan AR.** Four sessions in Workshop on Health Economics from Theory to Practice, Coriole Gourmet Retreat, South Australia, July 2010.

56. **Willan AR.** Value of information: what is it good for? NIH/AHRQ Conference on Methodological Challenges in Comparative Effectiveness Research, Bethesda MD, December 2010.
57. **Willan AR.** The beauty and the beast: simple randomization, versus everything else. CHES Research Day, Toronto, Canada, February 2011.
58. **Willan AR.** Value of Information (VOI) Methods: What are They Good For? CHES Research Day, Toronto, Canada, February 2011.
59. **Willan AR.** Determination of trial size: How large should our RCT be? Society for Clinical Trials. Vancouver, Canada, May 2011.
60. **Willan AR.** Why a Bayesian Be? Statistical Society of Canada, Wolfville, Canada, June 2011.

Past Research Funding

1. Canadian Medical Association, International Health Study. MacKenzie T (Principal Investigator), **Willan A**, Roberts J, Lees R. \$30,000, March 84 to June 85.]
2. Canadian Medical Association, Satisfaction with Obstetrical Care. MacKenzie T (Principal Investigator), **Willan A**, Roberts J, Lees R. \$62,700, May 86 to November 86.
3. Ontario Medical Association, Disease Severity and Hospital Resource Utilization. **Willan A** (Principal Investigator), MacKenzie T. \$12,000, November 85 to September 86.
4. Environmental Protection Branch, Health and Welfare Canada, The Health Effects of Indoor and Outdoor Air Pollution. **Willan A**. \$51,000, January 86 to March 88.
5. National Health Research and Development Program, Student Fellowship No. 6606-1382-47, University of Western Ontario. **Willan A**. \$18,000, January 77 to December 79.
6. National Cancer Institute of Canada, Clinical Trials Program, Pater J (Principal Investigator), Eisenhauer E, Shelley W, **Willan A**. \$6,324,000, April 82 - March 88.

7. Medical Research Council, Argon vs Krypton Laser in the Treatment of Age Related Macular Degeneration and Presumed Ocular Histoplasmosis. Cruess A (Principal Investigator), **Willan A**, Canny C, Gomolin J, Harvey P, Gonder J, Britton W, Howcroft M, Leonard B, Chew E, Mandelcorn M, Martin J, Chisholm L, Moffat K, Desroches G, Siebert L, Schwartz C, Boucher C, Dumas J, Labelle P, Kozousek V, Grant G, Schindler R, Marcil G, Shea M. \$650,000, April 86 - December 92
8. Health Care Financing Administration (U.S.) Patient Classification Systems: An Evaluation of the State of the Art. MacKenzie T (Principal Investigator), **Willan A**. \$2,200,000, June 87 - May 89.
9. Florida Hospital Medical Centre, Costs in Tertiary Non-teaching Hospitals. MacKenzie T (Principal Investigator), **Willan A**. \$135,000, November 87 - April 89.
10. Health Care Financing Administration (U.S.), Sensitivity and Specificity of Severity Systems in Monitoring Quality of Care. MacKenzie T (Principal Investigator), **Willan A**. \$950,000, March 89 - September 90.
11. National Health Research and Development Program, Patient Classification Systems: An Evaluation of the State of the Art: Pilot Project. MacKenzie T (Principal Investigator), **Willan A**. \$59,820, November 87 - May 88.
12. Natural Sciences and Engineering Research Council of Canada, Infrastructure Grant, Statistical Services. Allen B (Principal Grantee), **Willan A**. \$108,000, April 88 - March 91.
13. Association of Canadian Teaching Hospitals, Indirect Costs of Teaching. MacKenzie T (Principal Investigator), **Willan A**. \$55,000, January 88 - January 89.
14. Natural Sciences and Engineering Research Council of Canada, Operating Grant, Test of Hypothesis in non-nested regressions. **Willan A**. \$23,100, April 88 - March 91.
15. Physicians Services Incorporated, Detection of Minimal Disease in Non-Hodgkin's Lymphoma by Polymerase Chain Reaction Amplification of t(14:18). Berinstein N (Principal Investigator), **Willan A**. \$345,000, July 89 - June 92.
16. Medical Research Council, Biological Prognostic Factors in Non-Hodgkins Lymphoma. Sawka C (Principal Investigator), Berinstein N, **Willan A**. \$471,000, July 90 – June 93.
17. Canadian Council on Health Facilities Accreditation, Assessment of Health Outcomes Monitoring. MacKenzie T (Principal Investigator), **Willan A**, Greenaway-Coates A. \$1,500,000, February 90 - August 91.
18. Medical Research Council, Canadian multicentre randomized controlled trial of prophylactic induction of labour and serial antenatal monitoring in the post-term patient.

Hannah M (Principal Investigator), Hannah W, Milner R, Ohlsson A, **Willan A**, \$1,800,000, July 1 86 - March 31 92.

19. Ontario Mental Health, Measuring Processes of Care and Parental Psychosocial Well-being. King G (Principal Investigator), Rosenbaum P, **Willan A**. \$150,000, June 91 - May 93.
20. Ontario Ministry Health, Lower extremity splinting for children with cerebral palsy. Evans C (Principal Investigator), Gowland C, Rosenbaum P, **Willan A**, Russell D, Weber D. \$200,000, June 91 - May 93.
21. Alzheimer Association of Ontario, Development and evaluation of decisional aid to screen from competency to complete a health care directive. Molloy M (Principal Investigator), Silberfield M, Guyatt G, **Willan A**, Singer P. \$70,000, April 1, 1992 - March 31, 1993.
22. Medical Research Council, A Double-Blind Randomized Trial of Sucralfate Versus Ranitidine - the Incidence of Nosocomial Pneumonia. Cook D (Principal Investigator), Guyatt G, **Willan A**, Fuller H, Hall R, Winton T, Noseworthy T, Leasa D, Rutledge F, Powles P. \$380,165, July 1, 1992 - June 30, 1994.
23. Ontario Ministry Health, The withdrawal of life support in critically ill patients. Cook D (Principal Investigator), Jaeschke R, Ali M, Guyatt G, **Willan A**. \$13,226, August 1, 1991 - April 30, 1992.
24. Ontario Ministry Health and National Cancer Institute of Canada, A randomized trial of different strategies for the investigation of metastatic disease in potentially operable lung cancer. Guyatt G (Principal Investigator), Goldberg M, Shamji F, Inculet R, Finley R, Deslauriers J, Bethune D, **Willan A**. \$1,073,390, October 1, 1991 - March 31, 1995.
25. Ontario Ministry of Health, Neurodevelopmental Clinical Research Unit, Health-system linked research infrastructure grant to do research relevant to the Association of Treatment Centres of Ontario. Rosenbaum P (Principal Investigator), Law M, King G, Gowland C, **Willan A**. \$2,500,000, June 1, 1989 - May 31, 1994.
26. Ontario Ministry of Health, Supportive Cancer Care Research Unit, Health-system linked research infrastructure grant to do research relevant to supportive care in cancer patients. Whelan T (Principal Investigator), Browman G, Gafni A, Gilbert R, Levine M, Sellick S, **Willan A**, Willms D. \$1,760,000, June 1, 1991 - April 30, 2001.
27. Medical Research Council, A Multicentre Randomized Controlled Trial of Induction of Labour in Term Pregnancies With Premature Rupture of the Membranes, Hannah M (Principal Investigator), Ohlsson A, Hodnett E, Wang E, **Willan A**. \$1,500,000, June 1, 1991 - May 31, 1995. Renewed, June 1, 1995 - April 30, 2001.
28. National Health Research and Development Program, Systematic Overviews of the Predictors of Adolescent Pregnancy and the Effectiveness of Adolescent Pregnancy

- Prevention Interventions. Mitchell A (Principal Investigator), Oxman A, Guyatt G, Farewell V, Cameron R, **Willan A**, Scott F, Underwood J. \$49,225, June 1992 - May 1995.
29. National Cancer Institute of Canada, The effect of smoking cessation on response to radiation in head and neck cancer patients. Browman G (Principal Investigator), Hodson I, **Willan A**, Sellick S. \$278,000, May 1993 - April 1996.
 30. Ontario Ministry of Health, The analgesic prescription self-evaluation tool. Browman G (Principal Investigator), **Willan A**, Sellick S. \$68,379, October 1993 - March 1996.
 31. Medical Research Council of Canada, Canadian implantable defibrillator study. Connolly S (Principal Investigator), Gent M, **Willan A**. \$1,193,000, September 1990 - June 1995.
 32. Medical Research Council of Canada, Canadian trial of physiologic pacing. Connolly S (Principal Investigator), Gent M, **Willan A**. \$2,200,000, July 1993 - June 1996.
 33. Agency for Health Care Policy & Development, Systematic application of a health care directive. Molloy W (Principal Investigator), Guyatt G, **Willan A**. \$1,225,476, June 1994 - May 1997.
 34. National Cancer Institute of Canada, The development of a decision aid for early breast cancer. Whelan T (Principal Investigator), **Willan A**. \$31,114, July 95 - June 96. (#006282).
 35. National Cancer Institute of Canada, RCT of a decision aid in non-negative breast cancer. Whelan T (Principal Investigator), **Willan A**, Gafni A, Browman G. \$144,332, July 95 - June 97. (#006296).
 36. Medical Research Council of Canada, Canadian health economic assessment of physiologic pacing. O'Brien B (Principal Investigator), **Willan A**, Connolly S, Gent M. \$388,330, July 1995 - June 1999.
 37. Medical Research Council of Canada, The Term Breech Trial. Hannah M (Principal Investigator), Milne K, Saigal S, **Willan A** \$1,948,176, January 1997 - September 2001.
 38. Canadian Breast Cancer Research Initiative, Caring at Home for Women with Advanced Breast Cancer. Grundfeld E (Principal Investigator), **Willan A**, Crooks D, Angus D. \$466,664, June 1997 - Sept 2001.
 39. Canadian Breast Cancer Research Initiative, Identification of Factors for Repeat Biennial Breast Screening. Rand C (Principal Investigator), McAuley R, Charles C, **Willan A**. \$160,000, June 1997 - May 1999.
 40. National Institute of Health–US, The Nursing Supportive Care in Labour Trial (NSCIL). Hodnett E (Principal Investigator), Hannah M, **Willan A**. \$1,312,929, September 1998 - August 2001.

41. Canadian Institutes of Health Research, Effect of Exercise on Women with Polycystic Ovarian Syndrome (PCOS). Hannah ME (Principal Investigator), Laredo S, Librach C, Feig D, Rodgers C, **Willan A**, Casper R, Leiter L. \$902,237, 2000-2002.
42. Canadian Institutes of Health Research, Labour Position Trial. Hodnett ED (Principal Investigator), Stremler R, Hannah ME, Petryshen P, Stevens BJ, **Willan A**. \$206,868, 2001-2003.
43. Canadian Institutes of Health Research, Two-year outcomes of infants and mothers enrolled in the Term Breech Trial. Whyte H (Principal Investigator), Hannah ME, Hodnett E, Amankwah K, King R, Hannah W, Saigal S, **Willan A**, Gafni A. \$321,955, 1999-2004.
44. Canadian Institutes of Health Research, Multiple vs single courses of antenatal corticosteroids for preterm birth. Murphy K (Principal Investigator), Hannah M, Ohlsson A, Amankwah K, Matthews S, Kelly E, Aghajafari F, **Willan A**, Saigal S, Gafni A. \$3,428,405, 2000-2006.
45. Physician's Services Incorporated Foundation, An Investigation into Interactions Between COX-2 Selective NSAIDs and Warfarin and the Risk of Bleeding in Patients who are Receiving these Drugs Concomitantly. Douketis J (Principal Investigator), Holbrook A, Crowther M, **Willan A**. \$79,376, 2000-2001.
46. Physician's Services Incorporated Foundation, Randomized control trial of casting vs Air-Stirrup ankle brace in children with acute low-risk fractures. Boutis K (Principal Investigator), Schuh, S, **Willan A**, Narayanan U. \$150,500 2003-2005.
47. Child Neurology Society/Child Neurology Foundation, Towards the Establishment of Standards of Practice and the Initiation of Multi-Centre, Multi-National Clinical Trials for Neonates and children with Stroke. deVeber G (Principal Investigator), **Willan A**. \$75,000, 2002-2004.
48. Canadian Institutes of Health Research, SELAN (Structured Early Labour Assessment and care by Nurses) Trial. Hodnett ED (Principal Investigator), Stremler R, **Willan A**, Fraser W, Gafni A, \$2,662,672, 2003-2007.
49. National Science and Engineering Council, Development of Statistical Methodology in Cost-Effectiveness Analysis. **Willan AR** (Principal Investigator) \$55,000, 2003-2008.
50. Canadian Institutes of Health Research, A conceptual framework for outcome measurement in children: Consequences for health economic evaluation and decision- making. Ungar W (Principal Investigator), **Willan A**, Marshall D, Feldman B, Wright J. \$225,000, 2003-2006.

51. University of Toronto, Dean's Fund. Goldman R (Principal Investigator), Mikrogianakis, **Willan A**, Koren G. Sublingual versus oral midazolam for laceration repair in the pediatric emergency department. \$10,000, 2003-2005.
52. Canadian Institutes of Health Research, Conventional versus liposomal amphotericin: an economic evaluation. Parshuram C, Upton A (Principal Investigators), Ungar W, Doyle J, **Willan A**. \$50,828. 2004-2005.
53. Physician's Services Incorporated Foundation, Emergency Department Rapid Intravenous Rehydration for Pediatric Gastroenteritis: A Randomized Controlled Trial. Freedman S (Principal Investigator), Parkin P, Schuh S, **Willan A**. \$156,000, 2006-2007.
54. Bloorview Research Institute, Functional Outcomes Following Orthopaedic Surgery Based On Gait Laboratory Versus Observational Gait Analysis In Ambulatory Children With Cerebral Palsy: A Pilot Randomized Controlled Trial. Narayana U (Principal Investigator), **Willan AR**, *et al.* \$25,015, 2007-2008.
55. Canadian Institutes of Health Research, Early External Cephalic Version 2 Trial. Hutton E (Principal Investigator) Hannah, M, **Willan AR**, Ross S, Gafni A, \$2,853,717, 2003-2009.
56. Canadian Institutes of Health Research, The Tips for Infant and Parental Sleep (TIPS) Trial. Stremler R (Principal Investigator), **Willan AR**, *et al.* \$405,344, 2007-2009.
57. Canadian Institutes of Health Research, Infant and Maternal Factors Associated with Attendance at Neonatal Follow-up Programs. Stevens B (Principal Investigator), **Willan AR**, *et al.* \$180,000, 2007-2010.

Current Research Funding

1. Canadian Institutes of Health Research, Multiple Courses Of Antenatal Corticosteroids For Preterm Birth Study: 5 Year Follow-Up (MACS-5). Asztalos E (Principal Investigator), Hannah M, Ohlsson A, Ross S, Matthews S, Murphy K, **Willan AR**, Saigal S, Gafni A. \$3,585,161, 2005-2012.
2. Canadian Institutes of Health Research, The Twin Birth Study. Barrett J (Principal Investigator), Hannah M, **Willan A**, Ross S, Hutton E, *et al.*, \$8,608,045, 2003-2011.
3. Canadian Institutes of Health Research, Translating Research on Pain in Children (Team Grant). Stevens B (Principal Investigator), **Willan AR**, *et al.* \$4,054,611, 2006-2011.
4. Physician's Services Incorporated Foundation, Impact of Oximetry on Disposition in Acute Bronchiolitis. Schuh S (Principal Investigator), Freedman S, Coates A, Parkin P, Allen U, **Willan AR**, Ungar W, DaSilva Z. \$163,000 2008-2011.

5. National Science and Engineering Council, Expected Value of Information and Optimal Trial Design. **Willan AR** (Principal Investigator) \$70,000, 2008-2013.
6. Canadian Institutes of Health Research, The Bedside Paediatric Early Warning System: a cluster randomized trial of mortality and processes of care. Parshuram C (Principal Investigator), **Willan AR**, *et al.* \$3,959,716, 2010-2014.
7. Canadian Institutes of Health Research, Sustainability of a multidimensional knowledge translation intervention to improve paediatric pain practices and outcomes. Bonnie Stevens (Principal Investigator), **Willan AR**, *et al.* \$998,061, 2011-2014.

Major Interests

statistical inference and power considerations for cost-effectiveness data, meta-analysis clinical trials methodology, crossover trials, non-nested regression, health services research, internet applications for clinical trials

Scholarly and Professional Activities

Grant Committees

- CHIR, Clinical Trials Panel 2001-2006
- NCIC, Panel I (Clinical Trials) 1998-2002
- CHIR, University-Industry Clinical Trials Panel, 1994-2001
- Canadian HIV Trials Network Scientific Panel, 1992-1997

Professional Organizations

- American Statistical Society, 1975-present
- Biometric Society, 1975-present
- Society for Clinical Trials, 1982-present
- Statistical Society of Canada, 1988-present
- International Health Economics Association, 2001-present

External Grant Reviews

- Canadian Institutes of Health Research
- British Columbia Research Institute
- National Cancer Institute of Canada
- Ontario Ministry of Health
- Canadian HIV Trials Network
- Clinical Trials Program, German Federal Ministry for Research and Education
- National Science and Engineering Research Council
- National Science Foundation, USA
- Economic and Social Research Council, UK

Journal Referee

- Technometrics
- Canadian Journal of Statistics
- Journal of Chronic Diseases
- American Statistician
- Controlled Clinical Trials
- Biometrics
- Health Economics
- BioMed Central
- Circulation
- Clinical Trials
- Cost Effectiveness and Resource Allocation
- Health Policy
- Health Policy and Planning
- Journal of Health Economics
- Journal of the Royal Statistical Society (A)
- Medical Decision Making
- Pharmcoeconomics
- Public Library of Science
- Scandinavian Journal of Statistics
- Statistica Sinica
- Statistics in Medicine
- Teaching and Learning in Medicine
- Value in Health

Graduate Teaching

Public Health Sciences, University of Toronto

CHL 5225H - Advanced Statistical Methods for Clinical Trials (2005-2007)

Health Policy, Management and Evaluation

HAD 5303H - Controlled Clinical Trials (2006-2007)

HAD 5313H - Advanced Design and Analysis Issues in Clinical Trials (2006-2008)

Health Research Methodology Program, McMaster University

CHS-HRM-702 - Introductory Biostatistics (1994)

CHS-HRM-730 - Clinical Trials (1995-2000)

CHS-HRM-733 - Statistical and Methodological Issues in Controlled Clinical Trials (1991-2008)

CHS-HRM 734 - Data Management in Health Research (1997-99)

CHS-HRM-751 - Research Methods using Non-experimental Designs (1991-92)

Department of Mathematics and Statistics, McMaster University

Math 756 - Biostatistics (1992-93, 1996)

Department of Population Medicine, University of Guelph

91-629 - Epidemiology and Biostatistics (1989)

Department of Mathematics & Statistics, University of Guelph
630-6990 - Statistical Consulting Internship (1987-88)
Department of Community Health and Epidemiology, Queen's University
EPID802 - Statistics for Epidemiologists (1982-87)
EPID810 - Design and Conduct of Controlled Clinical Trials (1984-87)

Current Graduate Student Supervision

Hong (Maggie) Chen, Ph.D.

“Using value of information methods to determine optimal designs for research in diagnostic tests, clinical trials in chronic diseases and the use of interim analyses.”

Ahmed Hossain, Ph.D. “Incorporating correlation in testing for differential expression of genes in microarray data.” (Co-supervisor)

Previous Graduate Student Supervision

Luisine Abrahamyan, PhD. “Development of new clinical trial design for rare Diseases.” (Co-supervisor)

Eleanor Pullenayegum (nee Pinto) (2005) Ph.D.

“Semi-parametric models for cost-effectiveness analysis: improving the efficiency of estimation from censored data”

Currently Assistant Professor, Department of Clinical Epidemiology and Biostatistics, McMaster University.

Min Su (2003) M.Sc.

“Factors associated with perinatal or neonatal mortality or serious neonatal morbidity in the term breech trial.”

Currently a PhD student at the University of Toronto.

Rina A Leyva (2001) M.Sc.

“Cost-effectiveness analysis when the willingness-to-accept is greater than the willingness-to-pay.”

Currently working as a statistician at a drug company in New Jersey.

Frank Cihon (1999) M.Sc.

“Meta-analysis: effects of the drug fosamax on osteoporosis.”

Joanna Biernacka (1998) M.Sc.

“Accounting for uncertainty in cost-effectiveness studies.”

Currently postdoctoral research associate at the Cambridge Institute for Medical Research, University of Cambridge.

Feng Chen (1994) M.Sc.

“Meta-analysis: fixed versus random effects.”

Currently working as a statistician at a drug company in Toronto.

David Hutchison (1993) M.Sc.

“Modelling vision in patients with age-related macular degeneration.”

Meiying Hou (1992) M.Sc.

“Linear models with nested error structure in prediction vision loss for patients with subretinal neovascular membranes.”

Administrative Responsibilities

Hospital for Sick Children

- Member of Committee for Computational Bioinformatics, 2002/09-2004/09
- Member of Dr Earl Silverman’s promotional review committee, 2002/11
- Member, Seed Grant Competition Committee, 2002/11-2004/12
- Chairman, DSMC for “A randomized, double-blind, placebo-controlled study of the effect of oral D-glucosamine hydrochloride on behaviour in Sanfilippo disease” 2002/11-2006/10
- Mentor to Joseph Beyene, 2002/11 - present
- Mentor and research advisor to Abhaya Kulkarni, 2003/01 - present
- Chairman of Dr Paul Dick’s promotional review committee, 2003/10
- Member of RESTRACOMP Committee, 2004/03-2006/04
- Chairman of Dr Gail McVey’s promotional review committee, 2004/07
- Mentor and research advisor to Robyn Stremmer, 2004/07 – 2005/11
- Mentor and research advisor to Lillian Sung, 2004/04 - present
- Mentor to Lisa Strug, 2007/08 – present
- Scientific Director, Quantitative Methods, Program in Child Health Evaluative Sciences, 2007/01 - present

Dalla Lana School of Public Health, University of Toronto

- Member of Graduate Student Admissions Committee, 2003/02-2007/05
- Member of Promotions and Tenure Committee, 2007/10-2008/01

Department of Clinical Epidemiology & Biostatistics, McMaster University

- Member of PhD Development Committee, 1991/04-1995/05
- Member of MSc Admissions Committee, 1993/04-2002/06
- Member of Graduate Education Committee, 1994/11- 2002/06
- Member of PhD Admissions Committee, 1996/04-2002/06
- Vice Chair, Research, 2000/09-2002/06

Faculty of Medicine, McMaster University

- Member of Safety Monitoring Committee of the ATIII Replacement Trial, 1991/08-1995/05
- Member of Alternative Payment Plan Working Group, 1992/02-1994/06
- Member of Faculty Scholarship Committee, 1999/04-March 2001/03

External

- Chairman of Safety Monitoring Committee for the ASA/Prednisone trial in women with unexplained recurrent fetal loss, 1990/01-1992/05
- Member of Data Monitoring and Safety Committee for the Clinical Trials Unit of the National Cancer Institute of Canada, 1996/04-2002/05
- Member of FSORC Management Committee, 1997/12-2001/06
- Member of FSORC Scholarship Committee, 1999/04-2002/06
- Member of Data Monitoring and Safety Committee for A Canadian Avandamet Normoglycemia Outcomes Evaluation, 2004/11-present
- Member of Data Monitoring and Safety Committee for Randomized Trial of Accelerated Partial Breast Irradiation, 2007/05-present